<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="pmc-domain-id">1765</journal-id><journal-id journal-id-type="pmc-domain">hvi</journal-id><journal-title-group><journal-title>Human Vaccines &amp; Immunotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">2164-5515</issn><issn pub-type="epub">2164-554X</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9980607</article-id><article-id pub-id-type="pmcid-ver">PMC9980607.1</article-id><article-id pub-id-type="pmcaid">9980607</article-id><article-id pub-id-type="pmcaiid">9980607</article-id><article-id pub-id-type="pmid">36656048</article-id><article-id pub-id-type="doi">10.1080/21645515.2022.2154098</article-id><article-id pub-id-type="publisher-id">2154098</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunotherapy - Other</subject></subj-group></article-categories><title-group><article-title>Epitope-based precision immunotherapy of Type 1 diabetes</article-title><alt-title alt-title-type="left-running-head">R. FIRDESSA FITE ET AL.</alt-title><alt-title alt-title-type="right-running-head">HUMAN VACCINES &amp; IMMUNOTHERAPEUTICS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Firdessa Fite</surname><given-names initials="R">Rebuma</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="an0002" ref-type="author-notes">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bechi Genzano</surname><given-names initials="C">Camillo</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="an0002" ref-type="author-notes">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mallone</surname><given-names initials="R">Roberto</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8328-8155</contrib-id><name name-style="western"><surname>Creusot</surname><given-names initials="RJ">Remi J.</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>a</label>Columbia Center for Translational Immunology, Department of Medicine, <institution-wrap><institution>Columbia University Irving Medical Center</institution></institution-wrap>, <city>New York</city>, <state>NY</state>, <country>USA</country></aff><aff id="aff0002"><label>b</label><institution-wrap><institution>Universit&#233; Paris Cit&#233;, Institut Cochin, CNRS, INSERM</institution></institution-wrap>, <city>Paris</city>, <country>France</country></aff><aff id="aff0003"><label>c</label>Assistance Publique H&#244;pitaux de Paris, Service de Diab&#233;tologie et Immunologie Clinique, Cochin Hospital, <institution-wrap><institution>H&#244;pitaux Universitaires de Paris Centre-Universit&#233; de Paris</institution></institution-wrap>, <city>Paris</city>, <country>France</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Remi J. Creusot <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:rjc2150@columbia.edu">rjc2150@columbia.edu</email> Columbia Center for Translational Immunology, Department of Medicine, <institution-wrap><institution>Columbia University Irving Medical Center</institution></institution-wrap>, 630 West 168th St, Mail Box 127, <city>New York</city>, <state>NY</state> 10032, <country>USA</country>.</corresp><fn id="an0002"><label>*</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>1</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2023</year></pub-date><volume>19</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">429263</issue-id><elocation-id seq="10">2154098</elocation-id><pub-history><event event-type="pmc-release"><date><day>19</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>03</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-04 23:25:14.683"><day>04</day><month>08</month><year>2023</year></date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>24</day><month>6</month><year>2023</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>24</day><month>6</month><year>2023</year></date></event><event event-type="received"><date><day>30</day><month>8</month><year>2022</year></date></event><event event-type="revised"><date><day>18</day><month>11</month><year>2022</year></date></event><event event-type="accepted"><date><day>29</day><month>11</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 The Author(s). Published with license by Taylor &amp; Francis Group, LLC.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="KHVI_19_2154098.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="KHVI_19_2154098.pdf"/><abstract><title>ABSTRACT</title><p>
Antigen-specific immunotherapies (ASITs) address important clinical needs in treating autoimmune diseases. However, Type 1 diabetes is a heterogeneous disease wherein patient characteristics influence responsiveness to ASITs. Targeting not only disease-relevant T cell populations, but also specific groups of patients using precision medicine is a new goal toward achieving effective treatment. HLA-restricted peptides provide advantages over protein as antigens, however, methods for profiling antigen-specific T cells need to improve in sensitivity, depth, and throughput to facilitate epitope selection. Delivery approaches are highly diverse, illustrating the many ways relevant antigen-presenting cell populations and anatomical locations can be targeted for tolerance induction. The role of persistence of antigen presentation in promoting durable antigen-specific tolerance requires further investigation. Based on the outcome of ASIT trials, the field is moving toward using patient-specific variations to improve efficacy, but challenges still lie on the path to delivering more effective and safer treatment to the T1D patient population.</p></abstract><abstract abstract-type="graphical"><title>GRAPHICAL ABSTRACT</title><fig position="anchor" id="uf0001" orientation="portrait"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KHVI_A_2154098_UF0001_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KHVI_A_2154098_UF0001_PB.jpg"/></alternatives></fig></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Type 1 diabetes</kwd><kwd>antigen-specific therapy</kwd><kwd>antigen-specific tolerance</kwd><kwd>epitope</kwd><kwd>precision medicine</kwd><kwd>endotype</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>NIH</institution><institution-id institution-id-type="open-funder-registry">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>R01AI142428</award-id></award-group><award-group><funding-source><institution-wrap><institution>Beatson Foundation</institution></institution-wrap></funding-source><award-id>2021-012</award-id></award-group><funding-statement>Studies on autoreactive T cells and antigen-specific tolerance in the Creusot lab are currently supported by NIH grants [R01AI142428, R56AI151217, R56DK131087] and Beatson Foundation grant [2021-012]. RFF was supported by postdoctoral fellowship 1-19-PMF-022 from the American Diabetes Association. Studies in the Mallone Lab are supported by The Leona M. and Harry B. Helmsley Charitable Trust [1901-03689], Agence Nationale de la Recherche [ANR-19-CE15-0014-01] and Fondation pour la Recherche Medicale [EQU20193007831]. R.M. received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements [115797 and 945268] (INNODIA and INNODIA HARVEST), which receive support from the EU Horizon 2020 program, JDRF, and The Leona M. &amp; Harry B. Helmsley Charitable Trust.</funding-statement></funding-group></support-group><counts><fig-count count="2"/><table-count count="3"/><ref-count count="123"/><page-count count="15"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec disp-level="1" id="s0001"><title>Type 1 diabetes and the need for antigen-specific therapies</title><p>Type 1 diabetes (T1D) is characterized by a progressive loss of insulin-producing &#946;-cells, which is primarily caused by autoreactive CD4+ and CD8+ T cells, as a result of impaired immune tolerance to &#946;-cell antigens. Several genetic factors contribute to the disease in at least two different ways. First, they may increase &#946;-cell fragility (increased oxidative and endoplasmic reticulum stress, sensitivity to proinflammatory cytokines).<sup><xref rid="cit0001" ref-type="bibr">1</xref></sup> Second, they may impair general tolerance mechanisms (as suggested by the occurrence of other autoimmune conditions in both T1D patients<sup><xref rid="cit0002" ref-type="bibr">2</xref></sup> and its animal model, the non-obese diabetic (NOD) mouse.<sup><xref rid="cit0003" ref-type="bibr">3</xref></sup> Administration of exogenous insulin for the last 100&#8201;years has saved countless lives; however, it can rarely achieve tight regulation of blood glucose levels, such that episodes of hyper- and hypoglycemia remain commonplace, and their recurrence leads to long-term complications.<sup><xref rid="cit0004" ref-type="bibr">4</xref></sup> Even when perfect glycemic control is achieved, there is still a residual 2- to 3-fold hazard ratio of death from any cause, particularly from cardiovascular disease, in T1D vs. non-diabetic individuals.<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup> Transplantation of pancreatic islets is limited by the paucity of donors and vigorous allogeneic immune responses to grafted islets requiring strong immunosuppression that substantially raises the risk of opportunistic infections, malignancies, and beta-cell toxicity.<sup><xref rid="cit0006" ref-type="bibr">6&#8211;8</xref></sup> While the use of autologous stem cell-derived &#946;-cells appears feasible in the future, these cells will remain vulnerable to autoreactive T cells.</p><p>Targeted immunotherapies aim to disable only relevant elements of the immune system in order to obviate global immunosuppression. Targeting specific immune cells or pathways is mostly about safety and leaving most of the immune system untouched, though this may increase efficacy in some cases. Biologics have supplanted immunosuppressive drugs in the last 10&#8211;20&#8201;years of clinical trials of T1D treatments, with the removal of specific immune cell types or blockade of specific immune pathways.<sup><xref rid="cit0009" ref-type="bibr">9</xref></sup> While more selective, these approaches still do not make any distinction between autoimmune cells and other immune cells. In contrast, antigen-specific immunotherapies (ASITs) offer a way to selectively engage autoreactive cells and neutralize them through various mechanisms of tolerance. For this to work, however, autoreactive T cells need to be engaged under appropriate conditions that favor tolerance. It is challenging to achieve these conditions in patients, not only because of the underlying local inflammation associated with the disease, but also because of genetic risk factors, some of which impair the induction and maintenance of tolerance (partly explaining how T1D developed in the first place). There are multiple stages of T1D disease progression (<xref rid="f0001" ref-type="fig">Figure 1</xref>), and ASITs are useful at stages where there are enough residual &#946;-cells left (or transplanted &#946;-cells) to protect by blocking autoimmune responses. Otherwise, controlled exogenous insulin delivery is required.
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>Stages of human T1D disease, corresponding endotype characteristics and windows of opportunities for ASIT.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KHVI_A_2154098_F0001_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KHVI_A_2154098_F0001_PB.jpg"/></alternatives><attrib>ASITs that induce durable tolerance can be used in high-risk patients, patients with recent onset who have sufficient residual C-peptide (reflecting endogenous insulin production) and, in the future, patients with grafted autologous stem cell-derived &#946;-cells. Patients with allogeneic islet grafts will require additional treatments to curb alloreactivity, although autoreactive Tregs may provide some protection through bystander suppression (<xref rid="f0002" ref-type="fig">Figure 2</xref>).</attrib></fig>
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><p>Bystander suppression.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KHVI_A_2154098_F0002_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KHVI_A_2154098_F0002_PB.jpg"/></alternatives><attrib>As ASIT cannot achieve full antigen coverage, they rely on bystander suppression as a key mechanism, through which immuno-regulatory T cell populations (mostly CD4+ Tregs) induced under appropriate conditions (left) can migrate to disease-relevant sites (e.g., pancreatic lymph nodes and pancreas; right), find immunogenic APCs that present their epitopes, downregulate the stimulatory function of these APCs and suppress autoreactive T cells that are concomitantly engaged by these APCs and/or prevent later stimulation by these APCs. As the diversity of epitopes presented by these APCs increases, the diversity of autoreactive T cells suppressed also increases. If APCs at these sites all present a very diverse set of epitopes, fewer epitopes may be needed for ASIT. Infectious tolerance is achieved when suppressed T cells themselves are turned into regulatory T cells, which is a difficult yet ideal scenario to achieve.</attrib></fig></p></sec><sec disp-level="1" id="s0002"><title>Why a need for precision therapy as well?</title><p>Precision therapy is a therapeutic approach that is tailored to an individual or group of patients according to the specific biological and molecular features of the disease (e.g. targeting a specific gene mutation in cancer). It constitutes another aspect of targeted therapy that is more about efficacy and maximizing responsiveness by taking the unique characteristics of patients into account.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> Some patients go through the different stages of disease progression (<xref rid="f0001" ref-type="fig">Figure 1</xref>) quite rapidly and are often diagnosed at a younger age, while other patients progress more slowly and develop diabetes well into adulthood. As T1D is both a multifactorial and polygenic autoimmune disease, it is likely that the number of genetic risk factors and the exposure to environmental influences and triggers, in combination, dictate the pace of disease progression. Due to this complexity, the factors that drive rapid versus slow progression remain poorly understood. Patients are also characterized by different autoantibody (AAb) profiles, with four major AAbs (against insulin, GAD65, IA-2 and ZnT8) being detectable in the serum prior to the onset of diabetes.<sup><xref rid="cit0011" ref-type="bibr">11</xref></sup> Individuals with two or more AAbs have a high risk of progressing to clinical T1D and those with one are at an intermediate risk.<sup><xref rid="cit0011" ref-type="bibr">11</xref></sup> Among genetic risk factors, the HLA class II locus shows the greatest association with T1D. For example, HLA-DRB1*04:01/2/4/5 (HLA-DR4, often inherited in linkage disequilibrium with HLA-DQB1*03:02 (HLA-DQ8)) and HLA-DRB1*03 (HLA-DR3, often linked with HLA-DQB1*02 (HLA-DQ2)) are most frequently found in T1D patients of European descent.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0013" ref-type="bibr">13</xref></sup> HLA haplotypes, both class I and class II, limit the number of peptides that can be presented for each antigen, and it is highly probable that key epitopes are preferentially presented by those aforementioned HLA-DR and DQ haplotypes. Moreover, early onset was associated with an AAb profile dominated by anti-insulin (primarily in individuals with at least one allele of HLA-DR4/DQ8 haplotype), whereas later onset featured more anti-GAD65 (particularly in subjects with two alleles of HLA-DR3/DQ2 haplotypes, although the HLA genetic background seems more heterogeneous in this subgroup).<sup><xref rid="cit0014" ref-type="bibr">14</xref>,<xref rid="cit0015" ref-type="bibr">15</xref></sup> It seems however that the faster clinical progression in early seroconverters reflects the earlier age of the first AAb appearance rather than an anti-insulin vs. anti-GAD65 pattern.<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup> There are other gene variants, environmental exposures and biomarkers that further characterize patients, and when all these characteristics are considered together, they can delineate discrete subtypes termed endotypes,<sup><xref rid="cit0013" ref-type="bibr">13</xref>,<xref rid="cit0017" ref-type="bibr">17</xref></sup> whereby certain characteristics often tend to correlate with one another in subsets of patients. Two patterns correlating HLA haplotype and AAb type have been noted so far in groups of patients:<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> one associating HLA-DR4(-DQ8) and anti-insulin as predominant and/or first and early appearing AAb, and another associating HLA-DR3(-DQ2) and anti-GAD65 as the predominant and/or first AAb (though appearing later in childhood).<sup><xref rid="cit0014" ref-type="bibr">14</xref>,<xref rid="cit0018" ref-type="bibr">18</xref></sup> However, it should be acknowledged that these endotypes do not encompass the whole range of heterogeneity of T1D.</p><p>The NOD mouse is a rare example of a polygenic and spontaneous model of autoimmune disease, and shows many commonalities with human T1D, including a large overlap in genetic susceptibility features, the &#946;-cell antigens targeted by T cells and other autoimmune conditions.<sup><xref rid="cit0003" ref-type="bibr">3</xref>,<xref rid="cit0019" ref-type="bibr">19</xref></sup> However, although it has been used extensively in T1D preclinical studies, it has been criticized for limited translatability of the efficacy of immunotherapies to T1D patients. This shortfall is related to the fact that the NOD mouse, as an inbred and genetically homogeneous strain, simply cannot represent the heterogeneity of the human T1D population. Interestingly, NOD mice have a unique MHC class II haplotype (I-A<sup>g7</sup>) that is highly similar to HLA-DQ8,<sup><xref rid="cit0020" ref-type="bibr">20</xref></sup> and they only develop anti-insulin AAb consistently.<sup><xref rid="cit0021" ref-type="bibr">21</xref></sup> Both I-A<sup>g7</sup> and DQ8 are known to present the same key epitope of insulin (B9:23), which was found to be essential for T1D to develop in NOD mice.<sup><xref rid="cit0022" ref-type="bibr">22</xref></sup> Therefore, the NOD mouse may constitute a reasonable model for the human endotype featuring HLA-DQ8 and anti-insulin, until humanized mice can be produced to model other endotypes.<sup><xref rid="cit0023" ref-type="bibr">23</xref></sup></p><p>In clinical trials that did not achieve their target, <italic toggle="yes">post-hoc</italic> data analyses were performed, whereby one objective was to determine what the best responders had in common. In the case of ASITs, it turns out that the HLA haplotype and/or the AAb profile could be indicators of responsiveness. In the Diabetes Prevention Type 1 (DPT-1) trial testing oral insulin to induce tolerance, protection was not significant when comparing all patients in treatment and placebo groups, but became significant when only patients with anti-insulin AAbs above 80&#8201;nU/mL were considered.<sup><xref rid="cit0024" ref-type="bibr">24</xref></sup> This suggests that patients who have a more pronounced AAb reactivity to an antigen may be more responsive to this antigen in ASIT. Mere positivity for the AAbs may not be correlated with responsiveness to therapy, as confirmed by a follow-up trial.<sup><xref rid="cit0025" ref-type="bibr">25</xref></sup> Across three trials involving the delivery of alum-formulated GAD65, it was generally observed that patients with the HLA-DR3-DQ2 haplotype were responsive, particularly if they also did not have the HLA-DR4-DQ8 haplotype.<sup><xref rid="cit0026" ref-type="bibr">26</xref></sup> These two examples support the idea that patient characteristics, which can be ascertained prior to treatment, can constitute useful predictors of responsiveness. As a result, newer ASIT trials are increasingly using these parameters as inclusion criteria (<xref rid="t0001" ref-type="table">Table 1</xref>), and if this practice improves responsiveness, additional <italic toggle="yes">post-hoc</italic> analyses may identify other parameters that correlate with efficacy.
<table-wrap position="float" id="t0001" orientation="landscape"><label>Table 1.</label><caption><p>Examples of clinical trials for antigen-specific immunotherapy of T1D (current and completed within the past five years).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="10%" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="5%" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Intervention</th><th align="center" colspan="1" rowspan="1">Components of ASITs</th><th align="center" colspan="1" rowspan="1">Endotype-related inclusion criteria</th><th align="center" colspan="1" rowspan="1">Status</th><th align="center" char="." colspan="1" rowspan="1">Trial size</th><th align="center" colspan="1" rowspan="1">Sponsor</th><th align="center" colspan="1" rowspan="1">NCT number</th><th align="center" colspan="1" rowspan="1">Stage</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">IMCY-T1D-001</td><td align="left" colspan="1" rowspan="1">Small synthetic peptide (Imotopes<sup>TM</sup>)</td><td align="left" colspan="1" rowspan="1">HLADR3-positive and/or HLADR4-positive</td><td align="left" colspan="1" rowspan="1">Completed in 2019</td><td align="char" char="." colspan="1" rowspan="1">41</td><td align="left" colspan="1" rowspan="1">Imcyse SA</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03272269">NCT03272269</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 1</td></tr><tr><td align="left" colspan="1" rowspan="1">IMCY-T1D-002</td><td align="left" colspan="1" rowspan="1">Small synthetic peptide (Imotopes<sup>TM</sup>)</td><td align="left" colspan="1" rowspan="1">HLADR3-positive and/or HLADR4-positive</td><td align="left" colspan="1" rowspan="1">Completed in 2019</td><td align="char" char="." colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">Imcyse SA</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04190693">NCT04190693</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 1</td></tr><tr><td align="left" colspan="1" rowspan="1">IMCY-T1D-003</td><td align="left" colspan="1" rowspan="1">Small synthetic peptide (Imotopes<sup>TM</sup>)</td><td align="left" colspan="1" rowspan="1">HLADR3-positive and/or HLADR4-positive</td><td align="left" colspan="1" rowspan="1">Recruiting</td><td align="char" char="." colspan="1" rowspan="1">108</td><td align="left" colspan="1" rowspan="1">Imcyse SA</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04524949">NCT04524949</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 2</td></tr><tr><td align="left" colspan="1" rowspan="1">Tolerogenic Dendritic Cell Vaccine<break/>PIpepTolDCs</td><td align="left" colspan="1" rowspan="1">Proinsulin Peptide (C19-A3)</td><td align="left" colspan="1" rowspan="1">Positive for DRB1&#8201;&#215;&#8201;04:01, *04:02 and/or *04:04 allele but without the protective HLA-DRB1&#8201;&#215;&#8201;15:01-DQA1&#8201;&#215;&#8201;01:02-DQB1&#8201;&#215;&#8201;06:02 haplotype</td><td align="left" colspan="1" rowspan="1">Recruiting</td><td align="char" char="." colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">City of Hope Medical Center</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04590872">NCT04590872</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 1</td></tr><tr><td align="left" colspan="1" rowspan="1">C19-A3 GNP</td><td align="left" colspan="1" rowspan="1">C19-A3 proinsulin peptide coupled to gold</td><td align="left" colspan="1" rowspan="1">Positive for DRB1&#8201;&#215;&#8201;0401 allele</td><td align="left" colspan="1" rowspan="1">Unknown</td><td align="char" char="." colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Cardiff University</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02837094">NCT02837094</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 1</td></tr><tr><td align="left" colspan="1" rowspan="1">GAD-Alum</td><td align="left" colspan="1" rowspan="1">rhGAD65-alum (Diamyd&#174;), Etanercept and Vitamin D</td><td align="left" colspan="1" rowspan="1">Positive for GAD65 antibodies</td><td align="left" colspan="1" rowspan="1">Completed in 2019</td><td align="char" char="." colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">Johnny Ludvigsson (Link&#246;ping University)</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02464033">NCT02464033</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 2</td></tr><tr><td align="left" colspan="1" rowspan="1">GABA-GAD</td><td align="left" colspan="1" rowspan="1">GAD and GABA</td><td align="left" colspan="1" rowspan="1">Positive for GAD65 antibodies</td><td align="left" colspan="1" rowspan="1">Completed In 2022</td><td align="char" char="." colspan="1" rowspan="1">101</td><td align="left" colspan="1" rowspan="1">University of Alabama at Birmingham</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02002130">NCT02002130</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 1</td></tr><tr><td align="left" colspan="1" rowspan="1">GAD-alum (Diamyd&#174;)</td><td align="left" colspan="1" rowspan="1">rhGAD65 adsorbed to Alhydrogel</td><td align="left" colspan="1" rowspan="1">HLA DR3-DQ2 haplotype</td><td align="left" colspan="1" rowspan="1">Recruiting</td><td align="char" char="." colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Link&#246;ping University</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05351879">NCT05351879</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 1<break/>Phase 2</td></tr><tr><td align="left" colspan="1" rowspan="1">GAD-alum (Diamyd&#174;)</td><td align="left" colspan="1" rowspan="1">rhGAD65, formulated in aluminum hydrogel</td><td align="left" colspan="1" rowspan="1">High GAD antibody titers (&gt;190&#8201;U/ml)</td><td align="left" colspan="1" rowspan="1">Completed in 2022</td><td align="char" char="." colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">Norwegian University of Science and Technology</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04262479">NCT04262479</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 2</td></tr><tr><td align="left" colspan="1" rowspan="1">GAD-Alum (Diamyd&#174;)</td><td align="left" colspan="1" rowspan="1">GAD-Alum (Diamyd) combined with Vitamin D and Ibuprofen</td><td align="left" colspan="1" rowspan="1">Elevated GAD65 antibodies</td><td align="left" colspan="1" rowspan="1">Completed in 2017</td><td align="char" char="." colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">Johnny Ludvigsson (Link&#246;ping University)</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01785108">NCT01785108</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 2</td></tr><tr><td align="left" colspan="1" rowspan="1">GAD-Alum (DIAGNODE-1)</td><td align="left" colspan="1" rowspan="1">Intra-lymph node rhGAD65 Alum&#8201;+&#8201;Vitamin D</td><td align="left" colspan="1" rowspan="1">Positive for GAD Antibodies</td><td align="left" colspan="1" rowspan="1">Completed in 2019</td><td align="char" char="." colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">Johnny Ludvigsson (Link&#246;ping University)</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02352974">NCT02352974</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 1</td></tr><tr><td align="left" colspan="1" rowspan="1">GAD-Alum DIAGNODE-2</td><td align="left" colspan="1" rowspan="1">Intra-lymph node Alhydrogel&#174;-formulated rhGAD65</td><td align="left" colspan="1" rowspan="1">Positive for GAD65 Antibodies</td><td align="left" colspan="1" rowspan="1">Completed in 2021</td><td align="char" char="." colspan="1" rowspan="1">109</td><td align="left" colspan="1" rowspan="1">Diamyd Medical AB</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03345004">NCT03345004</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 2</td></tr><tr><td align="left" colspan="1" rowspan="1">DIAGNODE-3</td><td align="left" colspan="1" rowspan="1">Intra-lymph node rhGAD65 formulated in Alhydrogel&#174;</td><td align="left" colspan="1" rowspan="1">HLA DR3-DQ2 haplotype and positive for GAD65 antibodies</td><td align="left" colspan="1" rowspan="1">Recruiting</td><td align="char" char="." colspan="1" rowspan="1">330</td><td align="left" colspan="1" rowspan="1">Diamyd Medical AB</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05018585">NCT05018585</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 3</td></tr><tr><td align="left" colspan="1" rowspan="1">DIAPREV-IT2</td><td align="left" colspan="1" rowspan="1">Alum-GAD (Diamyd&#174;) and Vitamin D3</td><td align="left" colspan="1" rowspan="1">Positive for GAD65 Antibodies plus at least one other</td><td align="left" colspan="1" rowspan="1">Terminated In 2019</td><td align="char" char="." colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1">Lund University</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02387164">NCT02387164</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 2</td></tr><tr><td align="left" colspan="1" rowspan="1">MultiPepT1De</td><td align="left" colspan="1" rowspan="1">Multiple Islet Peptides</td><td align="left" colspan="1" rowspan="1">HLA-DR4 (DRB1&#8201;&#215;&#8201;0401) genotype</td><td align="left" colspan="1" rowspan="1">Completed in 2018</td><td align="char" char="." colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">King&#8217;s College London</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02620332">NCT02620332</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 1</td></tr><tr><td align="left" colspan="1" rowspan="1">TOL-3021</td><td align="left" colspan="1" rowspan="1">Plasmid for the hINS gene</td><td align="left" colspan="1" rowspan="1">At least one of GAD65, IA-2, ZnT8, or insulin antibodies</td><td align="left" colspan="1" rowspan="1">Active, not recruiting</td><td align="char" char="." colspan="1" rowspan="1">78</td><td align="left" colspan="1" rowspan="1">Tolerion, Inc.</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03895437">NCT03895437</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 2</td></tr><tr><td align="left" colspan="1" rowspan="1">TOPPLE T1D</td><td align="left" colspan="1" rowspan="1">PPI, TGF-&#946;1, IL-10 and IL-2</td><td align="left" colspan="1" rowspan="1">At least one diabetes-related autoantibody present</td><td align="left" colspan="1" rowspan="1">Recruiting</td><td align="char" char="." colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</td><td align="center" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04279613">NCT04279613</ext-link></td><td align="center" colspan="1" rowspan="1">Phase 1</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p>rhGAD65 (recombinant human glutamic acid decarboxylase), GAD (glutamic acid decarboxylase), GABA (gamma-amino butyric acid), alum (aluminum hydroxide), HLA (human leukocyte antigens), PPI (preproinsulin), TGF-&#946;1 (transforming growth factor beta 1) and IL (Interleukin).</p></fn></table-wrap-foot></table-wrap></p><p>In sum, the success of ASIT for the treatment of T1D and other autoimmune diseases will benefit from being employed in a targeted manner, not only at the cellular level (targeting only autoreactive lymphocytes), but also at the individual level (tailored to endotype groups). Furthermore, we propose that the NOD mouse should be regarded and utilized more as a disease endotype model, and that promising treatments be next evaluated in the HLA-DR4-DQ8 endotype group, which is prominent in the T1D patient population.</p></sec><sec disp-level="1" id="s0003"><title>Why use peptides over full antigens?</title><p>As the studies described above used full proteins, the nature and number of epitopes that are ultimately presented on each HLA haplotype is not known. Because T cells selected as natural Tregs tend to have distinct T cell receptors (TCRs) from conventional T cells,<sup><xref rid="cit0027" ref-type="bibr">27</xref></sup> some MHC/peptide complexes may be more likely recognized by Tregs, in which case epitopes can be considered as &#8220;useful&#8221; for eliciting regulation. Peptides that engage conventional T cells may also be useful if they elicit deletion, anergy or conversion to peripheral Tregs, but that would depend more on the context of presentation rather than the nature of the peptide. Considering the full array of peptides that can be presented on different HLA haplotypes from a protein antigen, it is tempting to speculate that more useful GAD65 peptides are presented on HLA-DR3-DQ2 than on HLA-DR4-DQ8, leading to a better outcome in the GAD65-alum studies. Moreover, some peptides may not be as useful if they interfere with the display of useful peptides by competing for HLA occupancy. Thus, there may be an advantage of using a selection of peptides over the full antigen if these peptides are well-characterized and anticipated to preferentially stimulate Tregs and/or engage low-affinity T cells more effectively under tolerogenic conditions. Because of the ability of Tregs to suppress T cells across multiple specificities within and across antigens, provided that those other epitopes are displayed by the same antigen-presenting cells (APCs), it is not necessary to attempt to cover all possible epitopes in ASITs (<xref rid="f0002" ref-type="fig">Figure 2</xref>).</p><p>The array of epitopes that have been identified from T1D-relevant proteins is constantly growing, although their level of characterization and validation is highly varied. A search in the Immune Epitope Database (IEDB) yielded 8,234 MHC class I and 3,146 MHC class II human linear epitopes, the great majority of which were eluted from MHC. A more focused search on epitopes discovered by T cell assays returned 182 MHC class I and 401 MHC class II epitopes, as of the time of writing (<xref rid="t0002" ref-type="table">Table 2</xref>). These were typically identified by stimulating islet-infiltrating T cell clones with peptide libraries encompassing major &#946;-cell antigens.<sup><xref rid="cit0028" ref-type="bibr">28&#8211;30</xref></sup> The recent and comprehensive review by James et al. addresses most of these epitopes, providing a detailed analysis of their antigen source and HLA-restriction.<sup><xref rid="cit0031" ref-type="bibr">31</xref></sup> About 75% of epitopes recognized by CD8+ T cells are derived from insulin, ZnT8 and GAD65, and about the same percentage is restricted to the common HLA-A2 allele. About 80% of epitopes recognized by CD4+ T cells are derived from GAD65, insulin and IA-2, 1/3 are restricted to HLA-DR4 and 1/4 are restricted to HLA-DQ8. Still, these numbers do not reflect the reality but rather the current knowledge, which is itself biased toward those haplotypes most commonly found in T1D patients. The IEDB also provides detailed information about TCRs recognizing some of these epitopes on specific HLA haplotypes (V region usage and CDR3 sequence) sufficient to produce TCR-transgenic T cell transductants that may be used to validate the presentation of epitopes from various ASIT delivery platforms in vitro or using in vivo models.<sup><xref rid="cit0023" ref-type="bibr">23</xref></sup>
<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>Human T cell linear epitopes deposited in the Immune Epitope Database (IEDB) and validated by T cell assays, and corresponding TCRs identified. Filters applied: linear structure for epitope structure; Homo sapiens for both organism and host; type 1 diabetes mellitus for disease; include positive T cell assay; exclude B cell assays and MHC assays; further filtered on MHC class I, class II or specific HLA protein complex as indicated in the table). A more limited number of epitopes (third column) were from assays in which the TCR sequence of responding T cells was characterized (at least one chain in fourth column; or both alpha and beta chains in fifth column). One epitope can be recognized by multiple T cell clones (TCR alpha/beta pairs). Searches including both T cell and MHC assays (eluted peptides) yielded 8,234 epitopes for HLA class I and 3,146 epitopes for HLA class II. Data are accurate as of 11/02/2022.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="18%" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">MHC</th><th align="center" char="." colspan="1" rowspan="1">Total epitopes</th><th align="center" char="." colspan="1" rowspan="1">Epitopes recognized by TCRs</th><th align="center" char="." colspan="1" rowspan="1">Number of TCRs identified</th><th align="center" char="." colspan="1" rowspan="1">Number of paired TCRs (unique clones)</th><th align="center" colspan="1" rowspan="1">Main antigens</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><bold>HLA class I</bold></td><td align="char" char="." colspan="1" rowspan="1"><bold>182</bold></td><td align="char" char="." colspan="1" rowspan="1"><bold>24</bold></td><td align="char" char="." colspan="1" rowspan="1"><bold>135</bold></td><td align="char" char="." colspan="1" rowspan="1"><bold>79</bold></td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">HLA-A</td><td align="char" char="." colspan="1" rowspan="1">125</td><td align="char" char="." colspan="1" rowspan="1">17</td><td align="char" char="." colspan="1" rowspan="1">122</td><td align="char" char="." colspan="1" rowspan="1">66</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">HLA-A *02:01</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">110</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">14</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">120</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">64</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">ZnT8 (31), insulin (26), GAD65 (9), IA-2 (8), IGRP (6)</italic></td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">HLA-A *03:01</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">11</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">0</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">0</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">0</italic></td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">HLA-B</td><td align="char" char="." colspan="1" rowspan="1">13</td><td align="char" char="." colspan="1" rowspan="1">6</td><td align="char" char="." colspan="1" rowspan="1">6</td><td align="char" char="." colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Insulin (6), GAD65 (6)</td></tr><tr><td align="left" colspan="1" rowspan="1">HLA-C</td><td align="char" char="." colspan="1" rowspan="1">4</td><td align="char" char="." colspan="1" rowspan="1">3</td><td align="char" char="." colspan="1" rowspan="1">7</td><td align="char" char="." colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Insulin (4)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>HLA class II</bold></td><td align="char" char="." colspan="1" rowspan="1"><bold>401</bold></td><td align="char" char="." colspan="1" rowspan="1"><bold>34</bold></td><td align="char" char="." colspan="1" rowspan="1"><bold>182</bold></td><td align="char" char="." colspan="1" rowspan="1"><bold>47</bold></td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">HLA-DP</td><td align="char" char="." colspan="1" rowspan="1">3</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">IA-2 (2), insulin (1)</td></tr><tr><td align="left" colspan="1" rowspan="1">HLA-DQ</td><td align="char" char="." colspan="1" rowspan="1">66</td><td align="char" char="." colspan="1" rowspan="1">24</td><td align="char" char="." colspan="1" rowspan="1">35</td><td align="char" char="." colspan="1" rowspan="1">35</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">HLA-DQB1&#8201;&#215;&#8201;02:01</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">6</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">6</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">6</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">6</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Insulin (6)</italic></td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">HLA-DQB1&#8201;&#215;&#8201;03:02</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">53</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">20</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">29</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">29</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Insulin (33), IA-2 (8), GAD65 (4), IAPP (2), HIPs (2)</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">HLA-DR</td><td align="char" char="." colspan="1" rowspan="1">119</td><td align="char" char="." colspan="1" rowspan="1">12</td><td align="char" char="." colspan="1" rowspan="1">148</td><td align="char" char="." colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">HLA-DRB1&#8201;&#215;&#8201;01:01</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">5</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">1</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">1</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">1</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">GAD65 (4), insulin (1)</italic></td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">HLA-DRB1&#8201;&#215;&#8201;03:01</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">3</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">0</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">0</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">0</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">IGRP (2), insulin (1)</italic></td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">HLA-DRB1&#8201;&#215;&#8201;04:01</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">75</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">4</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">140</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">6</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">GAD65 (29), insulin (11), IA-2 (11), HIPs (6), hexokinase-4 (5), IGRP (4)</italic></td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">HLA-DRB1&#8201;&#215;&#8201;04:02-05</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">7</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">2</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">2</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">2</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Insulin (4), GAD65 (3)</italic></td></tr></tbody></table></table-wrap></p><p>The identification of neoepitopes targeted by diabetogenic T cells has been a major advance in the T1D field. Aside from &#8220;native&#8221; peptides resulting from the simple proteolytic cleavage of known antigenic proteins, there are other types of peptides that have been hypothesized to play a significant role in expanding the pool of pathogenic T cells and/or in targeting them in ASIT:<sup><xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0033" ref-type="bibr">33</xref></sup>
<list list-type="order" id="list_0001"><list-item><p>Peptides resulting from the post-translational modification (PTM) of native peptides (deamidation, citrullination, etc.).<sup><xref rid="cit0032" ref-type="bibr">32</xref></sup></p></list-item><list-item><p>Peptides resulting from the fusion of peptides from different antigens (hybrid peptides) creating new epitopes centered on the junctions of the original two peptides.<sup><xref rid="cit0034" ref-type="bibr">34&#8211;36</xref></sup></p></list-item><list-item><p>Peptides encompassing new junctions produced from alternatively spliced mRNA occurring in islets but not in the thymus and other lymphoid tissues.<sup><xref rid="cit0037" ref-type="bibr">37&#8211;40</xref></sup></p></list-item><list-item><p>Peptides originating from defective ribosomal products (DRiP) whose expression may be increased under the influence of T1D-associated gene polymorphisms.<sup><xref rid="cit0041" ref-type="bibr">41</xref></sup></p></list-item><list-item><p>Artificial peptides (often termed mimotopes or altered peptide ligands) that either correspond to native peptides mutated to help fix anchoring on MHC in a particular conformation or register to enhance recognition by a specific type of T cells<sup><xref rid="cit0042" ref-type="bibr">42</xref></sup> or that were identified for their ability to stimulate islet-infiltrating T cells of unknown specificity.<sup><xref rid="cit0043" ref-type="bibr">43</xref></sup></p></list-item></list></p><p>These neoepitopes greatly increase the antigenic display that make up the specificities of diabetogenic T cells to the point that the use of a single protein may appear preposterous, no matter how many MHC-binding epitopes that single protein may produce. It is not yet clear whether certain types of neoepitopes are associated with specific endotypes, and whether some are early drivers of the disease or appear during later stages of disease. Because some of these neoepitopes may arise under certain stress or inflammatory conditions, it is probable that they are not produced and presented under steady state conditions and that tolerance to these neoepitopes is limited. Moreover, they are not templated in the genome and may therefore be preferentially recognized as &#8220;non-self.&#8221; Thus, the inclusion of neoepitopes in ASIT to build this tolerance may prove important. Using mimotopes, as well as native epitopes that are generally ignored,<sup><xref rid="cit0044" ref-type="bibr">44</xref></sup> increases the chance of targeting antigen-specific T cells that are more na&#239;ve (and likely easier to manipulate phenotypically) and possibly more frequent.</p><p>There are other advantages of using peptides over proteins for ASIT:
<list list-type="order" id="list_0002"><list-item><p>It is easier to synthesize peptides than to produce recombinant proteins. Peptides can be synthesized with specific mutations or chemical modifications that correspond to PTMs, and the chemical synthesis process circumvents issues of biological contaminants from protein-producing cells.</p></list-item><list-item><p>The use of peptides is more amenable to customizing the treatment of T1D patients grouped by endotypes, using a &#8220;mix &amp; match&#8221; approach.</p></list-item><list-item><p>Some delivery strategies are more compatible with the use of peptides than proteins.</p></list-item><list-item><p>Despite their shorter in-vivo half-life compared to proteins, potency and persistence of peptides can be improved by chemical modifications.<sup><xref rid="cit0045" ref-type="bibr">45</xref></sup></p></list-item></list></p><p>Moreover, just like proteins can be encoded by DNA vectors (as in DNA vaccines for T1D<sup><xref rid="cit0046" ref-type="bibr">46&#8211;50</xref></sup>), it is possible to express a wide variety of epitopes from a single vector,<sup><xref rid="cit0051" ref-type="bibr">51&#8211;53</xref></sup> with the same previously mentioned advantages. Endogenously encoded proteins and polypeptides have the added benefit of allowing the host cells to perform PTMs on them naturally under the appropriate conditions. DNA vectors are also cheaper to produce, and while the efficiency of DNA delivery remains relatively limited, one molecule generates many mRNA molecules, which in turn produces hundreds of proteins or polypeptides.<sup><xref rid="cit0054" ref-type="bibr">54</xref></sup></p><p>One limitation of using peptides over proteins is that they are unable to engage autoreactive B cells that only recognize conformational epitopes. It is unclear to what extent targeting &#946;-cell antigen-specific B cells for tolerance can help in blunting the overall autoimmune response, but one may speculate that anergized B cells serving as APCs may contribute to tolerization of T cells and/or regulatory B cells may help suppress autoreactive T cells. Several studies have suggested a beneficial involvement of regulatory B cells in treatment of T1D.<sup><xref rid="cit0055" ref-type="bibr">55&#8211;58</xref></sup></p></sec><sec disp-level="1" id="s0004"><title>What immune biomarkers and epitope characteristics may be used for customization?</title><p>The concept of endotype being relatively new, associations between patient characteristics and targetable antigen specificities are yet to be made. AAbs are reliable biomarkers that are routinely measured. While the number of AAbs informs on the relative risk of progressing to overt disease, the relative titer of each AAb may provide clues on dominant immune reactivities. As AAb-producing B cells require initial help from antigen-specific CD4+ T cells, this can provide an indirect indication of dominant T cell responses. However, it remains to be seen in other trials if the DPT-1 trial <italic toggle="yes">post-hoc</italic> results are generalizable and if AAb titers can be used for antigen selection to achieve significant responsiveness.</p><p>A more direct measurement of T cell specificities would be to perform multiplex MHC multimer analysis to determine whether certain antigen-specific T cell populations are expanded in the circulation, possibly delineating populations that are worth targeting. In this approach, MHC multimers are used, sometimes in pairs (with two different detectable conjugates) for most accurate detection of antigen-specific T cells, using conventional or spectral flow cytometry (fluorochrome-labeled), mass cytometry (heavy metal-labeled) or DNA sequencing (DNA barcode-labeled).<sup><xref rid="cit0059" ref-type="bibr">59</xref></sup> In T1D, approaches with combinatorial MHC multimers validated the existence of autoreactive CD8+ T cells specific to a wider array of antigens than previously anticipated.<sup><xref rid="cit0040" ref-type="bibr">40</xref>,<xref rid="cit0060" ref-type="bibr">60</xref></sup> The same approach can be used to analyze CD4+ T cells,<sup><xref rid="cit0061" ref-type="bibr">61</xref></sup> but has yet to be applied for T1D-relevant specificities. There are, however, several challenges to this approach:
<list list-type="order" id="list_0003"><list-item><p>Detection of autoreactive T cells is complicated by the fact that many of their TCRs are of relatively low affinity and thus signal may be weak.</p></list-item><list-item><p>This is an expensive approach. Even with high-throughput methods utilizing DNA barcodes, the high cost of MHC multimer manufacturing dramatically limits how comprehensive the analysis panel can be. However, the panels would be limited to using only MHC multimers matching the HLA haplotype of the tested individuals.</p></list-item><list-item><p>The frequency of relevant antigen-specific T cells is very low in the blood, and it remains debated whether circulating autoreactive T cells provide a useful reflection of those infiltrating the target tissue (pancreatic islets in the case of T1D).</p></list-item></list></p><p>Studies using MHC multimers also reported that autoantigen-specific T cells are found in the circulation of healthy individuals, typically with similar frequencies,<sup><xref rid="cit0040" ref-type="bibr">40</xref>,<xref rid="cit0060" ref-type="bibr">60</xref>,<xref rid="cit0062" ref-type="bibr">62</xref>,<xref rid="cit0063" ref-type="bibr">63</xref></sup> which suggests that negative selection in the thymus may be limited to the highest affinity autoreactive T cells in all individuals, and that in T1D patients, it is mainly a defective regulation of the remaining T cells that allows them to be activated and become pathogenic.<sup><xref rid="cit0064" ref-type="bibr">64</xref></sup> Beyond detecting those T cells, it may be more important to determine their phenotype (i.e., whether these circulating T cells are more activated and antigen-experienced). Again, in MHC multimer-based analyses of circulating autoreactive CD8+ T cells comparing control and T1D donors, differences are difficult to pinpoint. Recently, a method combining DNA-barcode-labeled MHC tetramers, CITE-seq and TCR-seq (termed TetTCR-SeqHD) was employed to profile CD8+ T cells in control and T1D individuals.<sup><xref rid="cit0065" ref-type="bibr">65</xref></sup> While this approach provides a much deeper profiling of these rare T cells at the clonal level (thanks to TCR sequences), it is challenging to apply on a large scale (broad antigen-coverage by MHC multimers and large number of patients for screening purposes).</p><p>Another assessment of T cell specificities can be done by restimulating PBMCs with specific peptides and measuring cytokines produced in response using ELISPOT assays. In such study using insulin mimotopes, CD4+ T cells from both control and T1D donors generated IFN-&#947;+ spots.<sup><xref rid="cit0066" ref-type="bibr">66</xref></sup> However, the CD4+ T cells from control donors produced IL-10+ spots more frequently than those from T1D donors,<sup><xref rid="cit0066" ref-type="bibr">66</xref></sup> indicating that differences in phenotypes may be discernable to ascertain the relevance of certain antigen specificities.</p><p>Regardless of the approach used, building a comprehensive immune profile for patients and attempting to identify major/driver antigens may be a daunting task at this time, and greater automation and cost reduction will be required. While having more options (epitopes/antigens) to choose from may be helpful, using a large number of peptides for immunotherapy may not be required. The question is then: how many epitopes are enough in ASIT to achieve control of the disease? Several studies in NOD mice suggest that one or few peptides may be enough to achieve significant protection from disease onset, likely through bystander suppression and infectious tolerance (<xref rid="f0002" ref-type="fig">Figure 2</xref>), and these peptides were generally strong binders (<xref rid="t0003" ref-type="table">Table 3</xref>). In humans, clinical trials have been conducted with up to six HLA-DR4-restricted insulin- and IA2-derived peptides, which were believed to engage Tregs (<xref rid="t0001" ref-type="table">Table 1</xref>). These studies have in common that all peptides used targeted CD4+ T cells, with the rationale that induction/stimulation of antigen-specific Tregs can suppress across specificities, and with the presumption that the number of functional Tregs may be more important than their diversity.
<table-wrap position="float" id="t0003" orientation="landscape"><label>Table 3.</label><caption><p>Antigen-specific approaches pursued by biotech companies and academic laboratories.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="8%" align="left" span="1"/><col width="12%" align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Form of delivery</th><th align="center" colspan="1" rowspan="1">Approach</th><th align="center" colspan="1" rowspan="1">Disease</th><th align="center" colspan="1" rowspan="1">Peptide used</th><th align="center" colspan="1" rowspan="1">Route</th><th align="center" colspan="1" rowspan="1">Company/University</th><th align="center" colspan="1" rowspan="1">Stage</th><th align="center" colspan="1" rowspan="1">Link or Reference</th></tr></thead><tbody><tr><td rowspan="4" align="left" colspan="1">Free peptides</td><td align="left" colspan="1" rowspan="1">Mimotope with stronger MHCII-binding</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">Insulin<sub>9-23</sub> mimotope</td><td align="left" colspan="1" rowspan="1">SC</td><td align="left" colspan="1" rowspan="1">Helmholtz Zentrum M&#252;nchen</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1">Refs.<sup><xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0068" ref-type="bibr">68</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Apitopes&#174;: tolerogenic peptides</td><td align="left" colspan="1" rowspan="1">MS</td><td align="left" colspan="1" rowspan="1">Four myelin-derived peptides</td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">Worg Pharmaceuticals</td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.worgpharma.com" ext-link-type="uri">http://www.worgpharma.com</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Imotopes&#174;: thioredoxin-Ag to augment pMHC-TCR interactions</td><td align="left" colspan="1" rowspan="1">T1D, MS</td><td align="left" colspan="1" rowspan="1">PPI-derived peptide, MOG-derived peptide</td><td align="left" colspan="1" rowspan="1">SC</td><td align="left" colspan="1" rowspan="1">Imcyse/University of Leuven</td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.imcyse.com" ext-link-type="uri">https://www.imcyse.com</ext-link>, Ref.<sup><xref rid="cit0069" ref-type="bibr">69</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple insulin peptides</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">PPI<sub>C13-C32</sub>, PPI<sub>C19-A3</sub>, PPI<sub>C22-A5</sub>, IA2<sub>718-36</sub>, IA2<sub>752-75</sub>, IA2<sub>855-67</sub></td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">King&#8217;s College London</td><td align="left" colspan="1" rowspan="1">Phase 3</td><td align="left" colspan="1" rowspan="1">Ref.<sup><xref rid="cit0070" ref-type="bibr">70</xref></sup></td></tr><tr><td rowspan="3" align="left" colspan="1">Conjugated peptides</td><td align="left" colspan="1" rowspan="1">Galactose or N-acetyl-galactosamine-terminating Ags</td><td align="left" colspan="1" rowspan="1">T1D, MS</td><td align="left" colspan="1" rowspan="1">p31 mimotope, myelin-derived peptides</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">Anokion</td><td align="left" colspan="1" rowspan="1">IND, Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://anokion.com" ext-link-type="uri">https://anokion.com</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Soluble Ag Arrays (SAgAs)</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">p79 mimotope, 2.5HIP</td><td align="left" colspan="1" rowspan="1">SC</td><td align="left" colspan="1" rowspan="1">University of Kansas/Columbia University</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1">Ref.<sup><xref rid="cit0071" ref-type="bibr">71</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Abs conjugated peptides targeting DCs (aDEC, aDCIR)</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">p31 mimotope</td><td align="left" colspan="1" rowspan="1">IP</td><td align="left" colspan="1" rowspan="1">NIH</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1">Ref.<sup><xref rid="cit0072" ref-type="bibr">72</xref></sup></td></tr><tr><td rowspan="7" align="left" colspan="1">Peptide carrying-NPs</td><td align="left" colspan="1" rowspan="1">PLGA co-delivery of Ag and rapamycin</td><td align="left" colspan="1" rowspan="1">PBC</td><td align="left" colspan="1" rowspan="1">PDH-E2-derived peptide</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">Selecta Biosciences</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://selectabio.com" ext-link-type="uri">https://selectabio.com</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Liposome or gold NPs co-delivery of Ag and AhR ligand</td><td align="left" colspan="1" rowspan="1">T1D, MS</td><td align="left" colspan="1" rowspan="1">PPI-derived peptides, MOG<sub>35-55</sub></td><td align="left" colspan="1" rowspan="1">SC, IV</td><td align="left" colspan="1" rowspan="1">Antolrx/Pfizer</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://antolrx.com" ext-link-type="uri">https://antolrx.com</ext-link>, Ref.<sup><xref rid="cit0073" ref-type="bibr">73</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Synthetic HDL to deliver Ag</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">NOD Ag</td><td align="left" colspan="1" rowspan="1">SC</td><td align="left" colspan="1" rowspan="1">Evoq Therapeutics</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.evoqtherapeutics.com" ext-link-type="uri">https://www.evoqtherapeutics.com</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">pSER liposomes taken up as apoptotic cells</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">Ins<sub>90-110</sub> and Ins<sub>25-54</sub></td><td align="left" colspan="1" rowspan="1">IP</td><td align="left" colspan="1" rowspan="1">Ahead Therapeutics/Universitat Autonoma de Barcelona</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.aheadtherapeutics.com" ext-link-type="uri">https://www.aheadtherapeutics.com</ext-link>, Ref.<sup><xref rid="cit0074" ref-type="bibr">74</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">PLG NPs uptake by phagocytes</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">2.5HIP</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">University of Colorado/Northwestern University/Cour Pharmaceuticals</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://courpharma.com" ext-link-type="uri">https://courpharma.com</ext-link>, Ref.<sup><xref rid="cit0075" ref-type="bibr">75</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Super paramagnetic iron oxide NPs (Spions&#174;)</td><td align="left" colspan="1" rowspan="1">PV</td><td align="left" colspan="1" rowspan="1">Desmoglein 3-derived peptides</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">Topas Therapeutics</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://topas-therapeutics.com" ext-link-type="uri">https://topas-therapeutics.com</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">NPs made of polymerized ursodeoxycholic acid</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">INS (protein, adaptable to peptides)</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">Toralgen/Yale University</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://toralgen.com" ext-link-type="uri">https://toralgen.com</ext-link>, Ref.<sup><xref rid="cit0076" ref-type="bibr">76</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA carrying-NPs</td><td align="left" colspan="1" rowspan="1">Liposome with mRNA-encoding Ags</td><td align="left" colspan="1" rowspan="1">MS</td><td align="left" colspan="1" rowspan="1">MOG<sub>35-55</sub></td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">BioNTech/University of Mainz</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1">Ref.<sup><xref rid="cit0077" ref-type="bibr">77</xref></sup></td></tr><tr><td rowspan="3" align="left" colspan="1">DNA vectors</td><td align="left" colspan="1" rowspan="1">Plasmid encoding Ag and targeting lysosomal compartment</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">p31 mimotope</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">University of Barcelona</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1">Ref.<sup><xref rid="cit0078" ref-type="bibr">78</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Plasmid encoding Ag, TGF-&#946;1, IL-10, IL-2</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">PI (protein, adaptable to peptides)</td><td align="left" colspan="1" rowspan="1">SC</td><td align="left" colspan="1" rowspan="1">Novo Nordisk</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1">Ref.<sup><xref rid="cit0049" ref-type="bibr">49</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Plasmid encoding multiple Ags (Endotope)</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">Ins<sub>B9-23</sub> p8E and p8&#8201;G mimotope, p79 mimotope, Ins<sub>B9&#8211;23,</sub> GAD65<sub>286-300</sub>, GAD65<sub>524-543</sub>, Ins<sub>B15&#8211;23,</sub> IGRP<sub>206-214</sub></td><td align="left" colspan="1" rowspan="1">IM, ID</td><td align="left" colspan="1" rowspan="1">Columbia University</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1">Ref.<sup><xref rid="cit0053" ref-type="bibr">53</xref></sup></td></tr><tr><td rowspan="2" align="left" colspan="1">Modified bacteria</td><td align="left" colspan="1" rowspan="1">Lactococcus lactis expressing IL-10, Ag</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">PI (protein, adaptable to peptides), GAD<sub>375-575</sub></td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">Precigen Actobio/University of Leuven</td><td align="left" colspan="1" rowspan="1">Phase 1/2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://precigen.com" ext-link-type="uri">https://precigen.com</ext-link>, Refs.<sup><xref rid="cit0079" ref-type="bibr">79</xref>,<xref rid="cit0080" ref-type="bibr">80</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Bacterium-like particles</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">IA-2ic (protein, adaptable to peptides)</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">Wuhan University</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1">Ref.<sup><xref rid="cit0081" ref-type="bibr">81</xref></sup></td></tr><tr><td rowspan="3" align="left" colspan="1">Modified erythrocytes</td><td align="left" colspan="1" rowspan="1">RBCs (or PBMCs) coupled with Ag</td><td align="left" colspan="1" rowspan="1">MS</td><td align="left" colspan="1" rowspan="1">Seven myelin-derived peptides</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">Cellerys/Novartis/University of Zurich</td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cellerys.com" ext-link-type="uri">https://www.cellerys.com</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">RBCs loaded with Ag</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">p31 mimotope</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">SQZ Biotech</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://sqzbiotech.com" ext-link-type="uri">https://sqzbiotech.com</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">RBCs transduced with Ag</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">p31 mimotope</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">Rubius Therapeutics</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rubiustx.com" ext-link-type="uri">https://www.rubiustx.com</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Soluble pMHC complexes</td><td align="left" colspan="1" rowspan="1">Dimeric MHC II-peptide chimera</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">GAD65<sub>217-230</sub></td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">Mount Sinai School of Medicine</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1">Ref.<sup><xref rid="cit0082" ref-type="bibr">82</xref></sup></td></tr><tr><td rowspan="2" align="left" colspan="1">APCs/APNPs</td><td align="left" colspan="1" rowspan="1">Tolerogenic DCs</td><td align="left" colspan="1" rowspan="1">T1D</td><td align="left" colspan="1" rowspan="1">PI<sub>C19-A3</sub></td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">Leiden University, City of Hope Medical Center</td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1">Ref.<sup><xref rid="cit0083" ref-type="bibr">83</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Iron oxide NPs with large density arrays of pMHC (Navacims&#174;)</td><td align="left" colspan="1" rowspan="1">T1D, MS, PBC</td><td align="left" colspan="1" rowspan="1">GAD65<sub>555-567</sub>, PI<sub>76&#8211;90,</sub> IGRP<sub>13-25</sub>, MOG<sub>38-49</sub>, PDH-E2<sub>166-181</sub></td><td align="left" colspan="1" rowspan="1">IV, SC</td><td align="left" colspan="1" rowspan="1">Parvus Therapeutics/University of Calgary</td><td align="left" colspan="1" rowspan="1">Pre-clinical</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://parvustx.com" ext-link-type="uri">https://parvustx.com</ext-link>, Ref.<sup><xref rid="cit0084" ref-type="bibr">84</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="tfn0002"><p>Ag, Antigen; NP, nanoparticle; APCs, antigen-presenting cells; APNP, antigen-presenting nanoparticles; aDEC, anti-DEC205; aDCIR, anti-DCIR2; PLGA, poly(lactic-co-glycolic acid); pSER, phosphatidyl-serine; RBCs, red blood cells; DCs, dendritic cells; T1D, Type 1 diabetes; MS, multiple sclerosis; PBC, primary biliary cirrhosis; PV, pemphigus vulgaris; MOG, myelin oligodendrocyte glycoprotein; PI, proinsulin; PPI, preproinsulin; NOD, non-obese diabetic; IA, insulinoma-associated; HIP, hybrid insulin peptide; INS, insulin; PDH-E2, pyruvate dehydrogenase-E2; GAD, glutamic acid decarboxylase; IGRP, islet-specific glucose-6-phosphatase catalytic subunit-related protein; SC, subcutaneous; ID, intradermal, IV, intravenous; IP, intraperitoneal.</p></fn></table-wrap-foot></table-wrap></p><p>The choice of peptides may also be based on their properties, beyond their ability to bind specific HLA haplotypes. As alluded to earlier, certain PTMs and mutations can affect the position and strength of binding, but they can also enable recognition by additional and otherwise unresponsive populations of T cells. The outcome of the T cell response can be influenced by the affinity of TCR binding to the peptide/MHC complex, and similarly, by the avidity of TCR recognition, which can be modulated by varying the dose of peptide administered. For example, when two epitopes stimulating the same T cell clone (BDC2.5) were tested in soluble antigen array (SAgA) form in NOD mice, the stronger one (p79 mimotope<sup><xref rid="cit0043" ref-type="bibr">43</xref></sup> primarily induced a Tr1 (IL-10-producing) type of Tregs, with a lower dose needed to stimulate Foxp3+ Tregs, whereas the 2.5HIP peptide<sup><xref rid="cit0034" ref-type="bibr">34</xref></sup> (about 10-fold weaker than p79 in vitro) at the same dose only stimulated Foxp3+ Tregs.<sup><xref rid="cit0071" ref-type="bibr">71</xref></sup> The two peptides did not change the frequency of IFN-&#947;+ antigen-specific T cells, but rather induced IL-10+ T cells or stimulated Foxp3+ Tregs. In some cases, chemical modifications may change the properties of the peptide to functionally alter the phenotype of responding T cells. For example, Imcyse&#8217;s Imotopes<sup>TM</sup> are HLA class II-binding peptides fused with a small peptide motif with oxido-reductase activity, which confers cytolytic activity to the activated CD4+ T cells, resulting in the killing of autoantigen-presenting cells and autoreactive T cells around them<sup><xref rid="cit0069" ref-type="bibr">69</xref></sup> (<xref rid="t0003" ref-type="table">Table 3</xref>).</p><p>Once pre-filtering based on known HLA restriction is accomplished, epitopes may be selected based on the source antigen (with a focus on one or few antigens) and on how well they are characterized. Epitopes that are simply predicted or eluted from MHC do not provide as much confidence as those that have been demonstrated to induce a T cell response. In particular, those found to be recognized by islet-infiltrating T cells would be prioritized as highly relevant, and the list is growing,<sup><xref rid="cit0085" ref-type="bibr">85</xref></sup> especially with recent efforts on identifying and validating neoepitopes using T cells from pancreatic islets and lymphoid tissues rather than blood. Once a group of disease-relevant epitopes has been defined for a specific HLA haplotype, could a mix of epitopes covering multiple antigens be used as a blanket treatment? In other words, if a patient&#8217;s autoimmune response is dominated by reactivity against insulin, would introducing other antigens by ASIT be beneficial or detrimental? This is a question that has not yet been addressed because patients have so far only been treated with one antigen at a time, except in the MultiPepT1De trial in which they received peptides from both proinsulin and IA-2 (<xref rid="t0003" ref-type="table">Table 3</xref>),<sup><xref rid="cit0070" ref-type="bibr">70</xref></sup> and there is only one spontaneous mouse model, representing one endotype, available for testing. If epitopes from other antigens induce Tregs and all epitopes tend to be naturally presented by the same APCs, then one may speculate that covering many antigens would have a beneficial outcome. In contrast, if epitopes are presented under inappropriate conditions (leading to preferential stimulation of effector T cells), then adding other epitopes could be detrimental. Blanket coverage with diverse peptides from multiple antigens is costly, unless those peptides can all be produced from a single molecule (DNA or mRNA)<sup><xref rid="cit0051" ref-type="bibr">51</xref></sup> or recombinant protein.<sup><xref rid="cit0086" ref-type="bibr">86</xref></sup> For example, the Endotope platform enables expression of multiple MHC class I and II restricted epitopes from a DNA vaccine, whereby MHC class II epitopes are separately funneled from cytosol to endosome.<sup><xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0052" ref-type="bibr">52</xref></sup> An Endotope DNA vaccine including native epitopes and mimotopes and covering at least three different antigens was comparable in efficacy to a proinsulin-encoding DNA vaccine in preventing disease in NOD mice (insulin-dominated endotype).<sup><xref rid="cit0053" ref-type="bibr">53</xref></sup></p><p>Another outstanding question that remains unanswered is whether it is sufficient to target CD4+ T cells (if resulting in suppressive antigen-specific Tregs) in a disease like T1D wherein CD4+ and CD8+ T cells play a critical role. While there is evidence that some ASITs can result in deletion of autoreactive CD8+ T cells in patients, this appears to be limited to those reactive to the administered antigen.<sup><xref rid="cit0047" ref-type="bibr">47</xref></sup> The current favored approach for epitope-based ASIT is to achieve a sufficient level of suppression with a minimal set of key HLA class II epitopes that would be effective across all patients within the same HLA haplotype group. However, given that Treg stability may be an issue in some T1D patients, targeting and eliminating certain CD8+ T cells that are consistently expanded in T1D patients may function as a debulking therapy and increase protection from disease. The use of disease-irrelevant epitopes that activate Tregs and are co-delivered with disease-relevant epitopes may also be considered. For example, Tregitopes are IgG epitopes recognized by Tregs, which become mobilized around diabetogenic T cells when Tregitopes are co-delivered and co-presented with preproinsulin peptides, resulting in disease improvement.<sup><xref rid="cit0087" ref-type="bibr">87</xref></sup></p></sec><sec disp-level="1" id="s0005"><title>How can we deliver peptides to suitable locations and APCs in vivo?</title><p>Once epitopes are selected, the next challenge is to find suitable modalities to deliver them to appropriate locations where APCs and their environment are conducive to tolerance. <xref rid="t0003" ref-type="table">Table 3</xref> summarizes delivery strategies by companies and academic laboratories. The simplest form of delivery is by injection of peptides in soluble form. These peptides are most vulnerable to extracellular degradation and may diffuse widely (unless injected in a dense tissue), potentially resulting in relatively low density of epitope presentation. Multimerization of peptides or formulation in small nanoparticles (&lt;200&#8201;nm) achieves higher molecular weights that are more conducive of draining through lymphatics to achieve more specific accumulation in T cell-rich lymph nodes, and possibly spleen. Some nanoparticles, based on their chemical composition and net charge, are preferentially taken up by specific APCs that are tolerogenic in nature (e.g., marginal zone macrophages, liver sinusoidal endothelial cells).<sup><xref rid="cit0088" ref-type="bibr">88</xref>,<xref rid="cit0089" ref-type="bibr">89</xref></sup> Larger microparticles (as well as large macromolecules such as DNA plasmids) remain trapped in the tissue in which they are injected and rely on tissue APCs with the capacity to migrate to draining lymph nodes.<sup><xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0090" ref-type="bibr">90</xref></sup> Small and large particles have also been used to remodel the environment of the antigen uptake and/or presentation sites (with nanoparticles influencing lymph node environment<sup><xref rid="cit0091" ref-type="bibr">91</xref></sup> and microparticles modulating the inoculation site,<sup><xref rid="cit0092" ref-type="bibr">92</xref></sup> for example). <xref rid="t0003" ref-type="table">Table 3</xref> provides examples illustrating the variety of nanoparticle formulations that differ in size, properties, and content (co-delivery of drugs along with antigens). While some formulations are compatible with oral delivery,<sup><xref rid="cit0093" ref-type="bibr">93</xref></sup> antigens have also been delivered inside commensal bacteria for oral tolerance.<sup><xref rid="cit0079" ref-type="bibr">79</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0094" ref-type="bibr">94</xref></sup> Alternative to using nanoparticles, peptides may be grafted onto natural polymers (hyaluronic acid, to produce SAgA),<sup><xref rid="cit0071" ref-type="bibr">71</xref></sup> conjugated to glycopeptides that enhance uptake in liver<sup><xref rid="cit0095" ref-type="bibr">95</xref></sup> or to antibodies against APC surface markers<sup><xref rid="cit0072" ref-type="bibr">72&#8211;96</xref>&#8211;<xref rid="cit0098" ref-type="bibr">98</xref></sup> or associated with erythrocytes that are taken up by tolerogenic splenic macrophages by efferocytosis.<sup><xref rid="cit0099" ref-type="bibr">99</xref></sup> Peptides may be expressed from DNA or mRNA vaccines, which often require formulation into nanoparticles or liposomes to improve the delivery and control the biodistribution.<sup><xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></sup> Peptides can also be provided as already presented on MHC molecules, either on the surface of tolerogenic dendritic cells<sup><xref rid="cit0083" ref-type="bibr">83</xref></sup> or on the surface of small nanoparticles,<sup><xref rid="cit0084" ref-type="bibr">84</xref></sup> the latter providing TCR stimulation without any costimulation to tolerize T cells. These can be used for direct presentation to T cells following administration, without requiring any expression and/or processing. Finally, instead of inducing tolerance or eliciting Tregs with specific epitopes, it is possible to use epitope-specific TCRs to engineer Tregs for cell therapy.<sup><xref rid="cit0101" ref-type="bibr">101</xref></sup> This approach requires identification of islet antigen-specific TCRs from islet-infiltrating T cells with the appropriate HLA restriction and any Treg, and the patient&#8217;s T cells can be engineered ex vivo to replace the preexisting TCR with a new disease-relevant TCR, then expanded prior to re-infusion. The use of chimeric antigen receptor (CAR) Tregs affords the additional advantages of whole antigen recognition rather than a specific peptide/MHC complex and independence from HLA haplotype,<sup><xref rid="cit0101" ref-type="bibr">101</xref></sup> although this may also be a limitation when the antigen is not a surface antigen (like many &#946;-cell antigens) and different targets are needed. The issue of Treg stability is crucial as conversion of transferred epitope-specific Tregs to effector T cells in vivo could exacerbate the disease, and additional engineering methods or treatment to stabilize Treg function are actively sought.</p></sec><sec disp-level="1" id="s0006"><title>Thoughts on ensuring appropriate conditions of epitope presentation</title><p>When antigenic proteins or peptides are administered to individuals, it is difficult to tightly control the type of APCs that participate in their presentation, and the tissue environment in which these antigens are taken up which influences the phenotype of these APCs. Sites like liver and gut-associated lymphoid tissues generally provide a more tolerogenic environment,<sup><xref rid="cit0102" ref-type="bibr">102</xref>,<xref rid="cit0103" ref-type="bibr">103</xref></sup> whereas in spleen and lymph nodes, tolerance induction is more dependent on the type of APCs. When professional APCs (cells capable of maturing to elicit immunogenic responses) are involved, it is desirable to target non-inflamed environments and ensure that nothing administered with the antigens (e.g., chemical modifications, nanodelivery formulations, DNA/RNA motifs when expressing antigens) acts as immunogenic adjuvant while maximizing exposure to the extensive pool of circulating T cells. Specific dendritic cell populations (e.g., DEC205+&#8201;vs DCIR2+) have been targeted with specific antibodies that were conjugated with peptides<sup><xref rid="cit0072" ref-type="bibr">72</xref></sup><sup>&#8211;<xref rid="cit0096" ref-type="bibr">96&#8211;98</xref></sup> and reported to promote tolerance. Alternatively, nonprofessional APCs have been targeted, including hepatocytes,<sup><xref rid="cit0095" ref-type="bibr">95</xref>,<xref rid="cit0104" ref-type="bibr">104</xref></sup> liver sinusoidal endothelial cells (e.g., Topas&#8217; SPIONS<sup>TM</sup>, <xref rid="t0003" ref-type="table">Table 3</xref>), and lymph node stromal cells.<sup><xref rid="cit0105" ref-type="bibr">105</xref></sup> For example, hepatocyte-restricted delivery can be achieved using N-acetylgalactosamine-modified antigens<sup><xref rid="cit0095" ref-type="bibr">95</xref></sup> (approach used by Anokion, <xref rid="t0003" ref-type="table">Table 3</xref>) or using liver-specific promoter coupled with micro-RNA targets restricting expression in non-hematopoietic cells in the case of transgene-encoded antigens.<sup><xref rid="cit0104" ref-type="bibr">104</xref></sup> When the type of APCs cannot be restricted, codelivery of immunomodulatory drugs (e.g., rapamycin<sup><xref rid="cit0076" ref-type="bibr">76</xref>,<xref rid="cit0106" ref-type="bibr">106</xref></sup> or cytokines (e.g., IL-10)<sup><xref rid="cit0079" ref-type="bibr">79</xref>,<xref rid="cit0107" ref-type="bibr">107</xref></sup> with antigens helps maintain the tolerogenic function of APCs. Importantly, a single DNA vaccine encoding antigen and multiple cytokines (IL-2, IL-10 and TGF-&#946;) has been validated<sup><xref rid="cit0049" ref-type="bibr">49</xref></sup> and is being tested clinically, providing a 4-in-1 drug option that is easy and economical to manufacture.</p><p>A more broadly distributed exposure of epitopes via systemic delivery may help with engaging more autoreactive T cells in a shorter time frame, while local delivery that results in presentation at limited sites may require more prolonged exposure or more frequent administrations. Persistence of self-antigen presentation appears critical for the induction of immune tolerance (anergy/exhaustion and deletion) in CD4+ T cells<sup><xref rid="cit0108" ref-type="bibr">108&#8211;115</xref></sup> and CD8+ T cells,<sup><xref rid="cit0116" ref-type="bibr">116</xref>,<xref rid="cit0117" ref-type="bibr">117</xref></sup> regardless of whether APCs are DCs<sup><xref rid="cit0112" ref-type="bibr">112</xref>,<xref rid="cit0114" ref-type="bibr">114</xref></sup> or B cells.<sup><xref rid="cit0110" ref-type="bibr">110</xref>,<xref rid="cit0111" ref-type="bibr">111</xref></sup> In fact, prolonged antigen exposure can lead to tolerance even when APCs were initially in an immunogenic state.<sup><xref rid="cit0111" ref-type="bibr">111</xref>,<xref rid="cit0117" ref-type="bibr">117</xref></sup> However, in the case of DCs, T cells can maintain effector functions after at least 3.5&#8201;days of continuous antigen presentation,<sup><xref rid="cit0112" ref-type="bibr">112</xref></sup> suggesting that antigen exposure should be sustained longer. These studies used continuous or regulated transgenic expression of antigens, but in ASIT, the frequency of delivery and duration of antigen presentation after each delivery differ between delivery modalities, resulting in continuous or intermittent antigen exposure. Peptides have a short half-life, whereas those delivered via nanoparticles persist longer. Multivalent delivery of peptides as SAgAs also significantly prolonged antigen presentation in vivo.<sup><xref rid="cit0071" ref-type="bibr">71</xref></sup> Controlled release of peptides can be achieved by osmotic pumps,<sup><xref rid="cit0067" ref-type="bibr">67</xref></sup> but peptides remain subject to extracellular degradation, resulting in sustained yet limited peptide delivery. DNA vaccines can sustain antigen presentation for at least two weeks in NOD mice,<sup><xref rid="cit0053" ref-type="bibr">53</xref></sup> but exposure is relatively limited (local) and administration once or twice a week was required to achieve sufficient T cell engagement and significantly block disease progression.<sup><xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0053" ref-type="bibr">53</xref></sup> While frequent administrations may be required at first to achieve a sufficient level of tolerance, treatments may potentially be discontinued or reduced in dose or frequency for maintenance. The route and frequency of administration represent challenges for implementation and compliance in patients, for example if frequent injections are needed. When frequent administrations are required to maintain a sufficient and sustained exposure of epitopes to autoreactive T cells, the oral route stands out as the most attractive for patients if adequate antigen protection and T cell responses can be obtained.</p></sec><sec disp-level="1" id="s0007"><title>Outlook: what are major challenges to overcome?</title><p>The field of ASIT in T1D (and other autoimmune diseases) has witnessed significant advances with new methods that accelerate the discovery and validation of disease-relevant epitopes, new biomarkers and signatures. These strides enable the stratification of patients into endotypes and the prediction of responsiveness to therapy. In parallel, a burst of biotech activities that follow a diverse and promising array of approaches (<xref rid="t0003" ref-type="table">Table 3</xref>) to achieve adequate delivery and presentation of epitopes for tolerance has taken place.</p><p>There remain a series of challenges that most approaches are confronted with and will need to be further tackled in the next few years:</p><list list-type="order" id="list_0004"><list-item><p>Biomarkers: How do we validate whether a set of common autoantigens or epitopes is relevant for a specific patient? We need additional and reliable markers that can discern autoreactive T cells in the blood (also detected in healthy individuals) that play an active part in the disease.</p></list-item><list-item><p>Models: Preclinical evaluation of ASIT is hampered by the poor representation of patient heterogeneity in animal models. While the NOD mouse model was serendipitously discovered, the current knowledge of T1D patient genetics may inform the engineering of new mouse strains that spontaneously develop T1D. Alternatively, mice hosting human immune systems from T1D patients may be used to recapitulate certain disease characteristics and assess T cell responsiveness to therapy in comparison to control immune systems.<sup><xref rid="cit0023" ref-type="bibr">23</xref>,<xref rid="cit0118" ref-type="bibr">118</xref></sup></p></list-item><list-item><p>Combination therapy: Protection through the use of ASIT alone in patients has proved difficult to achieve and tolerance takes time to build up. Inductive treatments that dramatically, temporarily, and selectively disable effector T cell populations (e.g., with targeted biologics) may help reset the immune system before patients are subsequently &#8220;retrained&#8221; with ASIT to elicit regulation over a more controllable effector population.</p></list-item><list-item><p>Treg instability: This remains a major issue in the T1D field. Long-term maintenance of Treg numbers and function is as important as their induction. We need to better understand the signals that control Treg stability and lifespan. Continuous (and tolerogenic) antigen exposure and low-dose IL-2 may be some of the requirements, and ex vivo engineered epitope-specific Tregs might provide the ultimate weapon to potently regulate diabetogenic T cells.</p></list-item><list-item><p>Persistence of antigen presentation: For ASIT platforms in which the duration of antigen presentation is shorter than the frequency of administration, antigen exposure is intermittent. How this affects the tolerization process and T cell responses as compared to continuous exposure remains to be investigated more closely and deciphered to understand the requirements for durable tolerance.</p></list-item><list-item><p>Autoreactive T cell heterogeneity: While different flavors of Tregs may be induced, which may work synergistically, effector T cells may be more difficult to curb than previously thought. In addition to possible resistance to regulation by effector T cells,<sup><xref rid="cit0119" ref-type="bibr">119</xref>,<xref rid="cit0120" ref-type="bibr">120</xref></sup> a reservoir of self-replenishing stem-like autoreactive CD8+ T cells was recently uncovered in NOD mice<sup><xref rid="cit0121" ref-type="bibr">121</xref>,<xref rid="cit0122" ref-type="bibr">122</xref></sup> and are likely to exist also in humans,<sup><xref rid="cit0123" ref-type="bibr">123</xref></sup> which may subsist in the background and require its own targeting approach.</p></list-item></list></sec></body><back><ack><title>Acknowledgments</title><p>We thank Michael E. James for critical reading of our manuscript.</p></ack><sec sec-type="COI-statement" disp-level="1" id="s0008"><title>Disclosure statement</title><p>RJC is the inventor of the Endotope platform. The authors do not have other conflicts of interest to report in this area.</p></sec><sec disp-level="1" id="s0009"><title>Author contributions</title><p>RJC wrote the first draft. RFF, CBG and RM all contributed insights and references. RJC, RFF and CBG produced the tables and figures.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mallone</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Eizirik</surname><given-names>DL.</given-names></string-name></person-group><article-title>Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in Type 1 diabetes?</article-title><source>Diabetologia</source>. <year>2020</year>;<volume>63</volume>(<issue>10</issue>):<fpage>1999</fpage>&#8211;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00125-020-05176-7</pub-id>.<pub-id pub-id-type="pmid">32894310</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hughes</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Riddlesworth</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>DiMeglio</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Rickels</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>McGill</surname><given-names>JB.</given-names></string-name></person-group><article-title>Autoimmune diseases in children and adults with Type 1 diabetes from the T1D exchange clinic registry</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2016</year>;<volume>101</volume>:<fpage>4931</fpage>&#8211;<lpage>37</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2016-2478</pub-id>.<pub-id pub-id-type="pmid">27676394</pub-id><pub-id pub-id-type="pmcid">PMC7530541</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aubin</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Lombard-Vadnais</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Collin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Aliesky</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>McLachlan</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Lesage</surname><given-names>S</given-names></string-name></person-group>. <article-title>The NOD mouse beyond autoimmune diabetes</article-title>. <source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>874769</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2022.874769</pub-id>.<pub-id pub-id-type="pmid">35572553</pub-id><pub-id pub-id-type="pmcid">PMC9102607</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khadilkar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Oza</surname><given-names>C</given-names></string-name></person-group>. <article-title>Glycaemic control in youth and young adults: challenges and solutions</article-title>. <source>Diabetes Metab Syndr Obes</source>. <year>2022</year>;<volume>15</volume>:<fpage>121</fpage>&#8211;<lpage>29</lpage>. doi:<pub-id pub-id-type="doi">10.2147/DMSO.S304347</pub-id>.<pub-id pub-id-type="pmid">35046683</pub-id><pub-id pub-id-type="pmcid">PMC8759988</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lind</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Svensson</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Kosiborod</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gudbjornsdottir</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pivodic</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wedel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Dahlqvist</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Clements</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rosengren</surname><given-names>A</given-names></string-name></person-group>. <article-title>Glycemic control and excess mortality in Type 1 diabetes</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>:<fpage>1972</fpage>&#8211;<lpage>82</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1408214</pub-id>.<pub-id pub-id-type="pmid">25409370</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nellore</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fishman</surname><given-names>JA</given-names></string-name></person-group>. <article-title>The microbiome, systemic immune function, and allotransplantation</article-title>. <source>Clin Microbiol Rev</source>. <year>2016</year>;<volume>29</volume>:<fpage>191</fpage>&#8211;<lpage>99</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CMR.00063-15</pub-id>.<pub-id pub-id-type="pmid">26656674</pub-id><pub-id pub-id-type="pmcid">PMC4771220</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fishman</surname><given-names>JA</given-names></string-name></person-group>. <article-title>Infection in organ transplantation</article-title>. <source>Am J Transplant</source>. <year>2017</year>;<volume>17</volume>:<fpage>856</fpage>&#8211;<lpage>79</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ajt.14208</pub-id>.<pub-id pub-id-type="pmid">28117944</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lian</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>C</given-names></string-name></person-group>. <article-title>Cancer risk and mutational patterns following organ transplantation</article-title>. <source>Front Cell Dev Biol</source>. <year>2022</year>;<volume>10</volume>:<fpage>956334</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcell.2022.956334</pub-id>.<pub-id pub-id-type="pmid">35837331</pub-id><pub-id pub-id-type="pmcid">PMC9274140</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Roep</surname><given-names>BO</given-names></string-name>, <string-name name-style="western"><surname>Posgai</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wheeler</surname><given-names>DCS</given-names></string-name>, <string-name name-style="western"><surname>Peakman</surname><given-names>M</given-names></string-name></person-group>. <article-title>The challenge of modulating beta-cell autoimmunity in Type 1 diabetes</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2019</year>;<volume>7</volume>:<fpage>52</fpage>&#8211;<lpage>64</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-8587(18)30112-8</pub-id>.<pub-id pub-id-type="pmid">30528099</pub-id><pub-id pub-id-type="pmcid">PMC7322790</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Deligne</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>You</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mallone</surname><given-names>R</given-names></string-name></person-group>. <article-title>Personalized immunotherapies for Type 1 diabetes: who, what, when, and how?</article-title><source>J Pers Med</source>. <year>2022</year>;<volume>12</volume>:<fpage>542</fpage>. doi:<pub-id pub-id-type="doi">10.3390/jpm12040542</pub-id>.<pub-id pub-id-type="pmid">35455658</pub-id><pub-id pub-id-type="pmcid">PMC9031881</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Insel</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Dunne</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Chiang</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Dabelea</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gottlieb</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Greenbaum</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Herold</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Krischer</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Lernmark</surname><given-names>&#197;</given-names></string-name>, et al</person-group>. <article-title>Staging presymptomatic Type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association</article-title>. <source>Diabetes Care</source>. <year>2015</year>;<volume>38</volume>:<fpage>1964</fpage>&#8211;<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc15-1419</pub-id>.<pub-id pub-id-type="pmid">26404926</pub-id><pub-id pub-id-type="pmcid">PMC5321245</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Erlich</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Valdes</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Noble</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Carlson</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Varney</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Concannon</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mychaleckyj</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Todd</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Bonella</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fear</surname><given-names>AL</given-names></string-name>, et al</person-group>. <article-title>HLA DR-DQ haplotypes and genotypes and Type 1 diabetes risk: analysis of the Type 1 diabetes genetics consortium families</article-title>. <source>Diabetes</source>. <year>2008</year>;<volume>57</volume>:<fpage>1084</fpage>&#8211;<lpage>92</lpage>. doi:<pub-id pub-id-type="doi">10.2337/db07-1331</pub-id>.<pub-id pub-id-type="pmid">18252895</pub-id><pub-id pub-id-type="pmcid">PMC4103420</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ilonen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lempainen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Veijola</surname><given-names>R</given-names></string-name></person-group>. <article-title>The heterogeneous pathogenesis of Type 1 diabetes mellitus</article-title>. <source>Nat Rev Endocrinol</source>. <year>2019</year>;<volume>15</volume>:<fpage>635</fpage>&#8211;<lpage>50</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41574-019-0254-y</pub-id>.<pub-id pub-id-type="pmid">31534209</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krischer</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Lynch</surname><given-names>KF</given-names></string-name>, <string-name name-style="western"><surname>Lernmark</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hagopian</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Rewers</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>She</surname><given-names>JX</given-names></string-name>, <string-name name-style="western"><surname>Toppari</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ziegler</surname><given-names>A-G</given-names></string-name>, <string-name name-style="western"><surname>Akolkar</surname><given-names>B</given-names></string-name></person-group>. <article-title>Genetic and environmental interactions modify the risk of diabetes-related autoimmunity by 6 years of age: the TEDDY study</article-title>. <source>Diabetes Care</source>. <year>2017</year>;<volume>40</volume>:<fpage>1194</fpage>&#8211;<lpage>202</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc17-0238</pub-id>.<pub-id pub-id-type="pmid">28646072</pub-id><pub-id pub-id-type="pmcid">PMC5566280</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krischer</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Lynch</surname><given-names>KF</given-names></string-name>, <string-name name-style="western"><surname>Schatz</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Ilonen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lernmark</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hagopian</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Rewers</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>She</surname><given-names>J-X</given-names></string-name>, <string-name name-style="western"><surname>Simell</surname><given-names>OG</given-names></string-name>, <string-name name-style="western"><surname>Toppari</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study</article-title>. <source>Diabetologia</source>. <year>2015</year>;<volume>58</volume>:<fpage>980</fpage>&#8211;<lpage>87</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00125-015-3514-y</pub-id>.<pub-id pub-id-type="pmid">25660258</pub-id><pub-id pub-id-type="pmcid">PMC4393776</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vehik</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bonifacio</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lernmark</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schatz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rewers</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>She</surname><given-names>J-X</given-names></string-name>, <string-name name-style="western"><surname>Toppari</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hagopian</surname><given-names>W</given-names></string-name>, et al</person-group>. <article-title>Hierarchical order of distinct autoantibody spreading and progression to Type 1 diabetes in the TEDDY study</article-title>. <source>Diabetes Care</source>. <year>2020</year>;<volume>43</volume>:<fpage>2066</fpage>&#8211;<lpage>73</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc19-2547</pub-id>.<pub-id pub-id-type="pmid">32641373</pub-id><pub-id pub-id-type="pmcid">PMC7440899</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Battaglia</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Becker</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bingley</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Bosi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Brusko</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>DiMeglio</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Evans-Molina</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Introducing the endotype concept to address the challenge of disease heterogeneity in Type 1 diabetes</article-title>. <source>Diabetes Care</source>. <year>2020</year>;<volume>43</volume>:<fpage>5</fpage>&#8211;<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc19-0880</pub-id>.<pub-id pub-id-type="pmid">31753960</pub-id><pub-id pub-id-type="pmcid">PMC6925574</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Giannopoulou</surname><given-names>EZ</given-names></string-name>, <string-name name-style="western"><surname>Winkler</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chmiel</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Matzke</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Scholz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Beyerlein</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Achenbach</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bonifacio</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ziegler</surname><given-names>A-G</given-names></string-name></person-group>. <article-title>Islet autoantibody phenotypes and incidence in children at increased risk for Type 1 diabetes</article-title>. <source>Diabetologia</source>. <year>2015</year>;<volume>58</volume>:<fpage>2317</fpage>&#8211;<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00125-015-3672-y</pub-id>.<pub-id pub-id-type="pmid">26138334</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anderson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bluestone</surname><given-names>J</given-names></string-name></person-group>. <article-title>The NOD mouse: a model of immune dysregulation</article-title>. <source>Annu Rev Immunol</source>. <year>2005</year>;<volume>23</volume>:<fpage>447</fpage>&#8211;<lpage>85</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115643</pub-id>.<pub-id pub-id-type="pmid">15771578</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Wucherpfennig</surname><given-names>KW</given-names></string-name>, <string-name name-style="western"><surname>Wiley</surname><given-names>DC</given-names></string-name></person-group>. <article-title>Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to Type 1 diabetes</article-title>. <source>Nat Immunol</source>. <year>2001</year>;<volume>2</volume>:<fpage>501</fpage>&#8211;<lpage>07</lpage>. doi:<pub-id pub-id-type="doi">10.1038/88694</pub-id>.<pub-id pub-id-type="pmid">11376336</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Nakayama</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Eisenbarth</surname><given-names>GS</given-names></string-name></person-group>. <article-title>Insulin as an autoantigen in NOD/human diabetes</article-title>. <source>Curr Opin Immunol</source>. <year>2008</year>;<volume>20</volume>:<fpage>111</fpage>&#8211;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.coi.2007.11.005</pub-id>.<pub-id pub-id-type="pmid">18178393</pub-id><pub-id pub-id-type="pmcid">PMC2268871</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nakayama</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Abiru</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Moriyama</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Babaya</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wegmann</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Hutton</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Elliott</surname><given-names>JF</given-names></string-name>, et al</person-group>. <article-title>Prime role for an insulin epitope in the development of Type 1 diabetes in NOD mice</article-title>. <source>Nature</source>. <year>2005</year>;<volume>435</volume>:<fpage>220</fpage>&#8211;<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature03523</pub-id>.<pub-id pub-id-type="pmid">15889095</pub-id><pub-id pub-id-type="pmcid">PMC1364531</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khosravi-Maharlooei</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Madley</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Borsotti</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>LMR</given-names></string-name>, <string-name name-style="western"><surname>Sharp</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Brehm</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Greiner</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Parent</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Sykes</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Modeling human T1D-associated autoimmune processes</article-title>. <source>Mol Metab</source>. <year>2022</year>;<volume>56</volume>:<fpage>101417</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molmet.2021.101417</pub-id>.<pub-id pub-id-type="pmid">34902607</pub-id><pub-id pub-id-type="pmcid">PMC8739876</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Skyler</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Krischer</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Wolfsdorf</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cowie</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Palmer</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Greenbaum</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cuthbertson</surname>, <given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rafkin-Mervis</surname>, <given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Chase</surname>, <given-names>HP</given-names></string-name>, <string-name name-style="western"><surname>Leschek</surname>, <given-names>E</given-names></string-name></person-group>. <article-title>Effects of oral insulin in relatives of patients with Type 1 diabetes: the diabetes prevention trial&#8211;Type 1</article-title>. <source>Diabetes Care</source>. <year>2005</year>;<volume>28</volume>:<fpage>1068</fpage>&#8211;<lpage>76</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diacare.28.5.1068</pub-id>.<pub-id pub-id-type="pmid">15855569</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study G</surname></string-name>, <string-name name-style="western"><surname>Krischer</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Schatz</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Bundy</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Skyler</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Greenbaum</surname><given-names>CJ</given-names></string-name></person-group>. <article-title>Effect of oral insulin on prevention of diabetes in relatives of patients with Type 1 diabetes: a randomized clinical trial</article-title>. <source>JAMA</source>. <year>2017</year>;<volume>318</volume>:<fpage>1891</fpage>&#8211;<lpage>902</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2017.17070</pub-id>.<pub-id pub-id-type="pmid">29164254</pub-id><pub-id pub-id-type="pmcid">PMC5798455</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hannelius</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Beam</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Ludvigsson</surname><given-names>J</given-names></string-name></person-group>. <article-title>Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed Type 1 diabetes</article-title>. <source>Diabetologia</source>. <year>2020</year>;<volume>63</volume>:<fpage>2177</fpage>&#8211;<lpage>81</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00125-020-05227-z</pub-id>.<pub-id pub-id-type="pmid">32754804</pub-id><pub-id pub-id-type="pmcid">PMC7476912</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lagattuta</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Nathan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pauken</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Jonsson</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Rao</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Sharpe</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Ishigaki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Raychaudhuri</surname><given-names>S</given-names></string-name></person-group>. <article-title>Repertoire analyses reveal T cell antigen receptor sequence features that influence T cell fate</article-title>. <source>Nat Immunol</source>. <year>2022</year>;<volume>23</volume>:<fpage>446</fpage>&#8211;<lpage>57</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41590-022-01129-x</pub-id>.<pub-id pub-id-type="pmid">35177831</pub-id><pub-id pub-id-type="pmcid">PMC8904286</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pathiraja</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kuehlich</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Krishnamurthy</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Loudovaris</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Coates</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Brodnicki</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Connell</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Kedzierska</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rodda</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer&#8211;restricted CD4+ T cells infiltrate islets in Type 1 diabetes</article-title>. <source>Diabetes</source>. <year>2015</year>;<volume>64</volume>:<fpage>172</fpage>&#8211;<lpage>82</lpage>. doi:<pub-id pub-id-type="doi">10.2337/db14-0858</pub-id>.<pub-id pub-id-type="pmid">25157096</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Babon</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>DeNicola</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Blodgett</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Crevecoeur</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Buttrick</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Maehr</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bottino</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Naji</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kaddis</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Elyaman</surname><given-names>W</given-names></string-name>, et al</person-group>. <article-title>Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with Type 1 diabetes</article-title>. <source>Nat Med</source>. <year>2016</year>;<volume>22</volume>:<fpage>1482</fpage>&#8211;<lpage>87</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.4203</pub-id>.<pub-id pub-id-type="pmid">27798614</pub-id><pub-id pub-id-type="pmcid">PMC5140746</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Michels</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Landry</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>McDaniel</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Campbell-Thompson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kwok</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Gottlieb</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Kappler</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>Q</given-names></string-name>, et al</person-group>. <article-title>Islet-derived CD4 T-cells targeting proinsulin in human autoimmune diabetes</article-title>. <source>Diabetes</source>. <year>2016</year>;<volume>66</volume>:<fpage>722</fpage>&#8211;<lpage>34</lpage>. doi:<pub-id pub-id-type="doi">10.2337/db16-1025</pub-id>.<pub-id pub-id-type="pmid">27920090</pub-id><pub-id pub-id-type="pmcid">PMC5319719</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>James</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Mallone</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kent</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>DiLorenzo</surname><given-names>TP</given-names></string-name></person-group>. <article-title>T-cell epitopes and neo-epitopes in Type 1 diabetes: a comprehensive update and reappraisal</article-title>. <source>Diabetes</source>. <year>2020</year>;<volume>69</volume>:<fpage>1311</fpage>&#8211;<lpage>35</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dbi19-0022</pub-id>.<pub-id pub-id-type="pmid">32561620</pub-id><pub-id pub-id-type="pmcid">PMC7306130</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>James</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Pietropaolo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mamula</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>Immune recognition of beta-cells: neoepitopes as key players in the loss of tolerance</article-title>. <source>Diabetes</source>. <year>2018</year>;<volume>67</volume>:<fpage>1035</fpage>&#8211;<lpage>42</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dbi17-0030</pub-id>.<pub-id pub-id-type="pmid">29784651</pub-id><pub-id pub-id-type="pmcid">PMC5961411</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Piganelli</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Mamula</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>James</surname><given-names>EA</given-names></string-name></person-group>. <article-title>The role of beta cell stress and neo-epitopes in the immunopathology of Type 1 diabetes</article-title>. <source>Front Endocrinol (Lausanne)</source>. <year>2020</year>;<volume>11</volume>:<fpage>624590</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fendo.2020.624590</pub-id>.<pub-id pub-id-type="pmid">33679609</pub-id><pub-id pub-id-type="pmcid">PMC7930070</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Delong</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wiles</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Bradley</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Barbour</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Reisdorph</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Armstrong</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Reisdorph</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>N</given-names></string-name>, et al</person-group>. <article-title>Pathogenic CD4 T cells in Type 1 diabetes recognize epitopes formed by peptide fusion</article-title>. <source>Science</source>. <year>2016</year>;<volume>351</volume>:<fpage>711</fpage>&#8211;<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aad2791</pub-id>.<pub-id pub-id-type="pmid">26912858</pub-id><pub-id pub-id-type="pmcid">PMC4884646</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jin</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Crawford</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Marrack</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kappler</surname><given-names>JW</given-names></string-name></person-group>. <article-title>N-terminal additions to the WE14 peptide of chromogranin a create strong autoantigen agonists in Type 1 diabetes</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2015</year>;<volume>112</volume>:<fpage>13318</fpage>&#8211;<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1517862112</pub-id>.<pub-id pub-id-type="pmid">26453556</pub-id><pub-id pub-id-type="pmcid">PMC4629350</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baker</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Jamison</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Haskins</surname><given-names>K</given-names></string-name></person-group>. <article-title>Hybrid insulin peptides are neo-epitopes for CD4 T cells in autoimmune diabetes</article-title>. <source>Curr Opin Endocrinol Diabetes Obes</source>. <year>2019</year>;<volume>26</volume>:<fpage>195</fpage>&#8211;<lpage>200</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MED.0000000000000490</pub-id>.<pub-id pub-id-type="pmid">31166225</pub-id><pub-id pub-id-type="pmcid">PMC6830731</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Diez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zeller</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Garza</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ricordi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hutton</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Eisenbarth</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Pugliese</surname><given-names>A</given-names></string-name></person-group>. <article-title>Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 Type 1 diabetes autoantigen</article-title>. <source>Diabetes</source>. <year>2001</year>;<volume>50</volume>:<fpage>895</fpage>&#8211;<lpage>900</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diabetes.50.4.895</pub-id>.<pub-id pub-id-type="pmid">11289059</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dogra</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Vaidyanathan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Prabakar</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Hutton</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Pugliese</surname><given-names>A</given-names></string-name></person-group>. <article-title>Alternative splicing of G6PC2, the gene coding for the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), results in differential expression in human thymus and spleen compared with pancreas</article-title>. <source>Diabetologia</source>. <year>2006</year>;<volume>49</volume>:<fpage>953</fpage>&#8211;<lpage>57</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00125-006-0185-8</pub-id>.<pub-id pub-id-type="pmid">16520917</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de Jong</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Abreu</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Verrijn Stuart</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>van der Slik</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Verhaeghen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Engelse</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Blom</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Staal</surname><given-names>FJT</given-names></string-name>, <string-name name-style="western"><surname>Gorus</surname><given-names>FK</given-names></string-name>, <string-name name-style="western"><surname>Roep</surname><given-names>BO</given-names></string-name></person-group>. <article-title>Alternative splicing and differential expression of the islet autoantigen IGRP between pancreas and thymus contributes to immunogenicity of pancreatic islets but not diabetogenicity in humans</article-title>. <source>Diabetologia</source>. <year>2013</year>;<volume>56</volume>:<fpage>2651</fpage>&#8211;<lpage>58</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00125-013-3034-6</pub-id>.<pub-id pub-id-type="pmid">24030068</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gonzalez-Duque</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Azoury</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Colli</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Afonso</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Turatsinze</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Nigi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lalanne</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Sebastiani</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Carr&#233;</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pinto</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Conventional and neo-antigenic peptides presented by &#946; cells are targeted by circulating na&#239;ve CD8+ T cells in Type 1 diabetic and healthy donors</article-title>. <source>Cell Metab</source>. <year>2018</year>;<volume>28</volume>:<fpage>946</fpage>&#8211;<lpage>60 e6</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmet.2018.07.007</pub-id>.<pub-id pub-id-type="pmid">30078552</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kracht</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>van Lummel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nikolic</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Joosten</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Laban</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>van der Slik</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>van Veelen</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Carlotti</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>de Koning</surname><given-names>EJP</given-names></string-name>, <string-name name-style="western"><surname>Hoeben</surname><given-names>RC</given-names></string-name>, et al</person-group>. <article-title>Autoimmunity against a defective ribosomal insulin gene product in Type 1 diabetes</article-title>. <source>Nat Med</source>. <year>2017</year>;<volume>23</volume>:<fpage>501</fpage>&#8211;<lpage>07</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.4289</pub-id>.<pub-id pub-id-type="pmid">28263308</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crawford</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Stadinski</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Michels</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nakayama</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pratt</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Marrack</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Eisenbarth</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kappler</surname><given-names>JW</given-names></string-name></person-group>. <article-title>Specificity and detection of insulin-reactive CD4+ T cells in Type 1 diabetes in the nonobese diabetic (NOD) mouse</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2011</year>;<volume>108</volume>:<fpage>16729</fpage>&#8211;<lpage>34</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1113954108</pub-id>.<pub-id pub-id-type="pmid">21949373</pub-id><pub-id pub-id-type="pmcid">PMC3189014</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Judkowski</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Pinilla</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Schroder</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tucker</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sarvetnick</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>DB</given-names></string-name></person-group>. <article-title>Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice</article-title>. <source>J Immunol</source>. <year>2001</year>;<volume>166</volume>:<fpage>908</fpage>&#8211;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.166.2.908</pub-id>.<pub-id pub-id-type="pmid">11145667</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tian</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kaufman</surname><given-names>DL</given-names></string-name></person-group>. <article-title>Designing personalized antigen-specific immunotherapies for autoimmune diseases&#8212;the case for using ignored target cell antigen determinants</article-title>. <source>Cells</source>. <year>2022</year>;<volume>11</volume>:<fpage>1081</fpage>. doi:<pub-id pub-id-type="doi">10.3390/cells11071081</pub-id>.<pub-id pub-id-type="pmid">35406645</pub-id><pub-id pub-id-type="pmcid">PMC8997884</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Skwarczynski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Toth</surname><given-names>I</given-names></string-name></person-group>. <article-title>Peptide-based synthetic vaccines</article-title>. <source>Chem Sci</source>. <year>2016</year>;<volume>7</volume>:<fpage>842</fpage>&#8211;<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1039/C5SC03892H</pub-id>.<pub-id pub-id-type="pmid">28791117</pub-id><pub-id pub-id-type="pmcid">PMC5529997</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Solvason</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>YP</given-names></string-name>, <string-name name-style="western"><surname>Peters</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Martinez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ramirez</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Ocampo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites</article-title>. <source>J Immunol</source>. <year>2008</year>;<volume>181</volume>:<fpage>8298</fpage>&#8211;<lpage>307</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.181.12.8298</pub-id>.<pub-id pub-id-type="pmid">19050246</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Roep</surname><given-names>BO</given-names></string-name>, <string-name name-style="western"><surname>Solvason</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gottlieb</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Abreu</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Harrison</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Eisenbarth</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Leviten</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hagopian</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Buse</surname><given-names>JB</given-names></string-name>, et al</person-group>. <article-title>Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8 + T cells in Type 1 diabetes</article-title>. <source>Sci Transl Med</source>. <year>2013</year>;<volume>5</volume>:<fpage>191ra82</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.3006103</pub-id>.<pub-id pub-id-type="pmcid">PMC4516024</pub-id><pub-id pub-id-type="pmid">23803704</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bot</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bot</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hughes</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wolfe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Woods</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>von Herrath</surname><given-names>M</given-names></string-name></person-group>. <article-title>Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice</article-title>. <source>J Immunol</source>. <year>2001</year>;<volume>167</volume>:<fpage>2950</fpage>&#8211;<lpage>55</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.167.5.2950</pub-id>.<pub-id pub-id-type="pmid">11509644</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pagni</surname><given-names>PP</given-names></string-name>, <string-name name-style="western"><surname>Chaplin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wijaranakula</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wesley</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Granger</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cracraft</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>O&#8216;Brien</surname>, <given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Perdue</surname>, <given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname>, <given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>, <given-names>S</given-names></string-name>, et al</person-group>. <article-title>Multicomponent plasmid protects mice from spontaneous autoimmune diabetes</article-title>. <source>Diabetes</source>. <year>2021</year>;71:157-169. doi:<pub-id pub-id-type="doi">10.2337/db21-0327</pub-id>.<pub-id pub-id-type="pmid">34389610</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tisch</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bui</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Arthos</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Serreze</surname><given-names>DV</given-names></string-name></person-group>. <article-title>Antigen-specific mediated suppression of &#946; cell autoimmunity by plasmid DNA vaccination</article-title>. <source>J Immunol</source>. <year>2001</year>;<volume>166</volume>:<fpage>2122</fpage>&#8211;<lpage>32</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.166.3.2122</pub-id>.<pub-id pub-id-type="pmid">11160264</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dastagir</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Postigo-Fernandez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Stoeckle</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Firdessa-Fite</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Creusot</surname><given-names>RJ</given-names></string-name></person-group>. <article-title>Efficient presentation of multiple endogenous epitopes to both CD4+ and CD8+ diabetogenic T cells for tolerance</article-title>. <source>Mol Ther Methods Clin Dev</source>. <year>2017</year>;<volume>4</volume>:<fpage>27</fpage>&#8211;<lpage>38</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.omtm.2016.12.002</pub-id>.<pub-id pub-id-type="pmid">28344989</pub-id><pub-id pub-id-type="pmcid">PMC5363322</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Postigo-Fernandez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Creusot</surname><given-names>RJ</given-names></string-name></person-group>. <article-title>A multi-epitope DNA vaccine enables a broad engagement of diabetogenic T cells for tolerance in Type 1 diabetes</article-title>. <source>J Autoimmun</source>. <year>2019</year>;<volume>98</volume>:<fpage>13</fpage>&#8211;<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaut.2018.11.003</pub-id>.<pub-id pub-id-type="pmid">30454875</pub-id><pub-id pub-id-type="pmcid">PMC6389442</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Postigo-Fernandez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Firdessa-Fite</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Creusot</surname><given-names>RJ</given-names></string-name></person-group>. <article-title>Preclinical evaluation of a precision medicine approach to DNA vaccination in Type 1 diabetes</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2022</year>;<volume>119</volume>:<fpage>e2110987119</fpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.2110987119</pub-id>.<pub-id pub-id-type="pmid">35385352</pub-id><pub-id pub-id-type="pmcid">PMC9169641</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schwanhausser</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Busse</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Dittmar</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Schuchhardt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wolf</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Selbach</surname><given-names>M</given-names></string-name></person-group>. <article-title>Global quantification of mammalian gene expression control</article-title>. <source>Nature</source>. <year>2011</year>;<volume>473</volume>:<fpage>337</fpage>&#8211;<lpage>42</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature10098</pub-id>.<pub-id pub-id-type="pmid">21593866</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Di Caro</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Phillips</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Engman</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Harnaha</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Trucco</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Giannoukakis</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Fiorina</surname><given-names>P</given-names></string-name></person-group>. <article-title>Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of Type 1 diabetes in NOD mice</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>:<fpage>e83575</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0083575</pub-id>.<pub-id pub-id-type="pmid">24465383</pub-id><pub-id pub-id-type="pmcid">PMC3894962</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boldison</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Da Rosa</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>FS</given-names></string-name></person-group>. <article-title>Dendritic cells license regulatory B cells to produce IL-10 and mediate suppression of antigen-specific CD8 T cells</article-title>. <source>Cell Mol Immunol</source>. <year>2020</year>;<volume>17</volume>:<fpage>843</fpage>&#8211;<lpage>55</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41423-019-0324-z</pub-id>.<pub-id pub-id-type="pmid">31728048</pub-id><pub-id pub-id-type="pmcid">PMC7395736</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Luo</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lundin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mejia-Cordova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hassani</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Blixt</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hjelmqvist</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lau</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Espes</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Carlsson</surname><given-names>P-O</given-names></string-name>, <string-name name-style="western"><surname>Sandler</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Interleukin-35 prevents development of autoimmune diabetes possibly by maintaining the phenotype of regulatory B cells</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>:<fpage>22</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms222312988</pub-id>.<pub-id pub-id-type="pmcid">PMC8657454</pub-id><pub-id pub-id-type="pmid">34884797</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hamad</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Donner</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Fousteri</surname><given-names>G</given-names></string-name></person-group>. <article-title>B cell-targeted immunotherapy for Type 1 diabetes: what can make it work?</article-title><source>Discov Med</source>. <year>2016</year>;<volume>21</volume>:<fpage>213</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="pmid">27115172</pub-id><pub-id pub-id-type="pmcid">PMC5266520</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bentzen</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Hadrup</surname><given-names>SR</given-names></string-name></person-group>. <article-title>Evolution of MHC-based technologies used for detection of antigen-responsive T cells</article-title>. <source>Cancer Immunol Immunother</source>. <year>2017</year>;<volume>66</volume>:<fpage>657</fpage>&#8211;<lpage>66</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00262-017-1971-5</pub-id>.<pub-id pub-id-type="pmid">28314956</pub-id><pub-id pub-id-type="pmcid">PMC5406421</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Azoury</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Tarayrah</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Afonso</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pais</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Colli</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Maillard</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lavaud</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Alexandre-Heymann</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez-Duque</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Verdier</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Peptides derived from insulin granule proteins are targeted by CD8(+) T cells across MHC class I restrictions in humans and NOD mice</article-title>. <source>Diabetes</source>. <year>2020</year>;<volume>69</volume>:<fpage>2678</fpage>&#8211;<lpage>90</lpage>. doi:<pub-id pub-id-type="doi">10.2337/db20-0013</pub-id>.<pub-id pub-id-type="pmid">32928873</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Uchtenhagen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rims</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Blahnik</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>IT</given-names></string-name>, <string-name name-style="western"><surname>Kwok</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Buckner</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>James</surname><given-names>EA</given-names></string-name></person-group>. <article-title>Efficient ex vivo analysis of CD4+ T-cell responses using combinatorial HLA class II tetramer staining</article-title>. <source>Nat Commun</source>. <year>2016</year>;<volume>7</volume>:<fpage>12614</fpage>. doi:<pub-id pub-id-type="doi">10.1038/ncomms12614</pub-id>.<pub-id pub-id-type="pmid">27571776</pub-id><pub-id pub-id-type="pmcid">PMC5013714</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Culina</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lalanne</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Afonso</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cerosaletti</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Pinto</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sebastiani</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kuranda</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nigi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Eugster</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>&#216;sterbye</surname><given-names>T</given-names></string-name>, et al</person-group>. <article-title>Islet-reactive CD8 + T cell frequencies in the pancreas, but not in blood, distinguish Type 1 diabetic patients from healthy donors</article-title>. <source>Sci Immunol</source>. <year>2018</year>;<volume>3</volume>. doi:<pub-id pub-id-type="doi">10.1126/sciimmunol.aao4013</pub-id>.<pub-id pub-id-type="pmcid">PMC5874133</pub-id><pub-id pub-id-type="pmid">29429978</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wiedeman</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Muir</surname><given-names>VS</given-names></string-name>, <string-name name-style="western"><surname>Rosasco</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>DeBerg</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Presnell</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Haas</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dufort</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Speake</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Greenbaum</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Serti</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow Type 1 diabetes progression</article-title>. <source>J Clin Invest</source>. <year>2020</year>;<volume>130</volume>:<fpage>480</fpage>&#8211;<lpage>90</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI126595</pub-id>.<pub-id pub-id-type="pmid">31815738</pub-id><pub-id pub-id-type="pmcid">PMC6934185</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Samassa</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mallone</surname><given-names>R</given-names></string-name></person-group>. <article-title>Self-antigens, benign autoimmunity and Type 1 diabetes: a beta-cell and T-cell perspective</article-title>. <source>Curr Opin Endocrinol Diabetes Obes</source>. <year>2022</year>;<volume>29</volume>:<fpage>370</fpage>&#8211;<lpage>78</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MED.0000000000000735</pub-id>.<pub-id pub-id-type="pmid">35777965</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>KY</given-names></string-name>, <string-name name-style="western"><surname>Schonnesen</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Sebastian</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Y-W</given-names></string-name>, <string-name name-style="western"><surname>Balderas</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kulkarni-Date</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>High-throughput and high-dimensional single-cell analysis of antigen-specific CD8(+) T cells</article-title>. <source>Nat Immunol</source>. <year>2021</year>;<volume>22</volume>:<fpage>1590</fpage>&#8211;<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41590-021-01073-2</pub-id>.<pub-id pub-id-type="pmid">34811538</pub-id><pub-id pub-id-type="pmcid">PMC9184244</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nakayama</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>McDaniel</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Fitzgerald-Miller</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kiekhaefer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Snell-Bergeon</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Davidson</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Rewers</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gottlieb</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kappler</surname><given-names>JW</given-names></string-name>, et al</person-group>. <article-title>Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and Type 1 diabetic subjects</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2015</year>;<volume>112</volume>:<fpage>4429</fpage>&#8211;<lpage>34</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1502967112</pub-id>.<pub-id pub-id-type="pmid">25831495</pub-id><pub-id pub-id-type="pmcid">PMC4394309</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Daniel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Weigmann</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bronson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>von Boehmer</surname><given-names>H</given-names></string-name></person-group>. <article-title>Prevention of Type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope</article-title>. <source>J Exp Med</source>. <year>2011</year>;<volume>208</volume>:<fpage>1501</fpage>&#8211;<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.20110574</pub-id>.<pub-id pub-id-type="pmid">21690251</pub-id><pub-id pub-id-type="pmcid">PMC3135372</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Serr</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Furst</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Achenbach</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Scherm</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Gokmen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Haupt</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Sedlmeier</surname><given-names>E-M</given-names></string-name>, <string-name name-style="western"><surname>Knopff</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shultz</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Willis</surname><given-names>RA</given-names></string-name>, et al</person-group>. <article-title>Type 1 diabetes vaccine candidates promote human Foxp3(+)Treg induction in humanized mice</article-title>. <source>Nat Commun</source>. <year>2016</year>;<volume>7</volume>:<fpage>10991</fpage>. doi:<pub-id pub-id-type="doi">10.1038/ncomms10991</pub-id>.<pub-id pub-id-type="pmid">26975663</pub-id><pub-id pub-id-type="pmcid">PMC4796321</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Malek Abrahimians</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Vander Elst</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Carlier</surname><given-names>VA</given-names></string-name>, <string-name name-style="western"><surname>Saint-Remy</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Thioreductase-containing epitopes inhibit the development of Type 1 diabetes in the NOD mouse model</article-title>. <source>Front Immunol</source>. <year>2016</year>;<volume>7</volume>:<fpage>67</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2016.00067</pub-id>.<pub-id pub-id-type="pmid">26973647</pub-id><pub-id pub-id-type="pmcid">PMC4773585</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>YF</given-names></string-name>, <string-name name-style="western"><surname>Powrie</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Arif</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>JHM</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Khatri</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lhuillier</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fountoulakis</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>Immune and metabolic effects of antigen-specific immunotherapy using multiple &#946;-cell peptides in Type 1 diabetes</article-title>. <source>Diabetes</source>. <year>2022</year>;<volume>71</volume>:<fpage>722</fpage>&#8211;<lpage>32</lpage>. doi:<pub-id pub-id-type="doi">10.2337/db21-0728</pub-id>.<pub-id pub-id-type="pmid">35073398</pub-id><pub-id pub-id-type="pmcid">PMC8965665</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Firdessa-Fite</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Leon</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Khosravi-Maharlooei</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Sestak</surname><given-names>JO</given-names></string-name>, <string-name name-style="western"><surname>Berkland</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Creusot</surname><given-names>RJ</given-names></string-name></person-group>. <article-title>Soluble antigen arrays efficiently deliver peptides and arrest spontaneous autoimmune diabetes</article-title>. <source>Diabetes</source>. <year>2021</year>;<volume>70</volume>:<fpage>1334</fpage>&#8211;<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.2337/db20-0845</pub-id>.<pub-id pub-id-type="pmid">33468513</pub-id><pub-id pub-id-type="pmcid">PMC8275897</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Price</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Hotta-Iwamura</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Beauchamp</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Tarbell</surname><given-names>KV</given-names></string-name></person-group>. <article-title>DCIR2+ cDC2 DCs and Zbtb32 restore CD4+ T-cell tolerance and inhibit diabetes</article-title>. <source>Diabetes</source>. <year>2015</year>;<volume>64</volume>:<fpage>3521</fpage>&#8211;<lpage>31</lpage>. doi:<pub-id pub-id-type="doi">10.2337/db14-1880</pub-id>.<pub-id pub-id-type="pmid">26070317</pub-id><pub-id pub-id-type="pmcid">PMC4587633</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kenison</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Jhaveri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Khadse</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tjon</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tezza</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nowakowska</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Plasencia</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Stanton</surname><given-names>VP</given-names></string-name>, <string-name name-style="western"><surname>Sherr</surname><given-names>DH</given-names></string-name>, et al</person-group>. <article-title>Tolerogenic nanoparticles suppress central nervous system inflammation</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2020</year>;<volume>117</volume>:<fpage>32017</fpage>&#8211;<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.2016451117</pub-id>.<pub-id pub-id-type="pmid">33239445</pub-id><pub-id pub-id-type="pmcid">PMC7749362</pub-id></mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Villalba</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez-Fernandez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ampudia</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Cano-Sarabia</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Perna-Barrull</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bertran-Cobo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ehrenberg</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Maspoch</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Vives-Pi</surname><given-names>M</given-names></string-name></person-group>. <article-title>Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for Type 1 diabetes</article-title>. <source>Artif Cells Nanomed Biotechnol</source>. <year>2020</year>;<volume>48</volume>:<fpage>77</fpage>&#8211;<lpage>83</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21691401.2019.1699812</pub-id>.<pub-id pub-id-type="pmid">31852325</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jamison</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Neef</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Goodspeed</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bradley</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Haskins</surname><given-names>K</given-names></string-name></person-group>. <article-title>Nanoparticles containing an insulin&#8211;ChgA hybrid peptide protect from transfer of autoimmune diabetes by shifting the balance between effector T cells and regulatory T cells</article-title>. <source>J Immunol</source>. <year>2019</year>;<volume>203</volume>:<fpage>48</fpage>&#8211;<lpage>57</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.1900127</pub-id>.<pub-id pub-id-type="pmid">31109955</pub-id><pub-id pub-id-type="pmcid">PMC6581587</pub-id></mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chaudhury</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bickerton</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>McHugh</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Siefert</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Rea</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Carballido</surname><given-names>JM</given-names></string-name>, et al</person-group>. <article-title>Metabolic and immunomodulatory control of Type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin</article-title>. <source>Nat Biomed Eng</source>. <year>2021</year>;<volume>5</volume>:<fpage>983</fpage>&#8211;<lpage>97</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41551-021-00791-0</pub-id>.<pub-id pub-id-type="pmid">34616050</pub-id></mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krienke</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kolb</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Diken</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Streuber</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kirchhoff</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bukur</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Akilli-&#214;zt&#252;rk</surname><given-names>&#214;</given-names></string-name>, <string-name name-style="western"><surname>Kranz</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Berger</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Petschenka</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis</article-title>. <source>Science</source>. <year>2021</year>;<volume>371</volume>:<fpage>145</fpage>&#8211;<lpage>53</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aay3638</pub-id>.<pub-id pub-id-type="pmid">33414215</pub-id></mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rivas</surname><given-names>EI</given-names></string-name>, <string-name name-style="western"><surname>Driver</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Garabatos</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Presa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mora</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Serreze</surname><given-names>DV</given-names></string-name>, <string-name name-style="western"><surname>Stratmann</surname><given-names>T</given-names></string-name></person-group>. <article-title>Targeting of a T cell agonist peptide to lysosomes by DNA vaccination induces tolerance in the nonobese diabetic mouse</article-title>. <source>J Immunol</source>. <year>2011</year>;<volume>186</volume>:<fpage>4078</fpage>&#8211;<lpage>87</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.0902395</pub-id>.<pub-id pub-id-type="pmid">21346228</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Takiishi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Korf</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Van Belle</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Robert</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Grieco</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Caluwaerts</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Galleri</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Spagnuolo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Steidler</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Van Huynegem</surname><given-names>K</given-names></string-name>, et al</person-group>. <article-title>Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice</article-title>. <source>J Clin Invest</source>. <year>2012</year>;<volume>122</volume>:<fpage>1717</fpage>&#8211;<lpage>25</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI60530</pub-id>.<pub-id pub-id-type="pmid">22484814</pub-id><pub-id pub-id-type="pmcid">PMC3336982</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robert</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gysemans</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Takiishi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Korf</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Spagnuolo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Sebastiani</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Van Huynegem</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Steidler</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Caluwaerts</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Demetter</surname><given-names>P</given-names></string-name>, et al</person-group>. <article-title>Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice</article-title>. <source>Diabetes</source>. <year>2014</year>;<volume>63</volume>:<fpage>2876</fpage>&#8211;<lpage>87</lpage>. doi:<pub-id pub-id-type="doi">10.2337/db13-1236</pub-id>.<pub-id pub-id-type="pmid">24677716</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mao</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Diao</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chi</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Oral delivery of the intracellular domain of the insulinoma-associated protein 2 (IA-2ic) by bacterium-like particles (BLPs) prevents Type 1 diabetes mellitus in NOD mice</article-title>. <source>Drug Deliv</source>. <year>2022</year>;<volume>29</volume>:<fpage>925</fpage>&#8211;<lpage>36</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10717544.2022.2053760</pub-id>.<pub-id pub-id-type="pmid">35311607</pub-id><pub-id pub-id-type="pmcid">PMC8942491</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stoica-Nazarov</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Surls</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kehl</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bona</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Olsen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Brumeanu</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Casares</surname><given-names>S</given-names></string-name></person-group>. <article-title>Reversal of Type 1 diabetes by a new MHC II-peptide chimera: &#8220;Single-epitope-mediated suppression&#8221; to stabilize a polyclonal autoimmune T-cell process</article-title>. <source>Eur J Immunol</source>. <year>2010</year>;<volume>40</volume>:<fpage>2277</fpage>&#8211;<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.1002/eji.200940094</pub-id>.<pub-id pub-id-type="pmid">20540111</pub-id></mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nikolic</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zwaginga</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Uitbeijerse</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Woittiez</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>de Koning</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Aanstoot</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Roep</surname>, <given-names>BO</given-names></string-name></person-group>. <article-title>Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide-for Type 1 diabetes</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2020</year>;<volume>8</volume>:<fpage>470</fpage>&#8211;<lpage>72</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-8587(20)30104-2</pub-id>.<pub-id pub-id-type="pmid">32723484</pub-id></mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Clemente-Casares</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Blanco</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ambalavanan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yamanouchi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Singha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fandos</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tsai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Garabatos</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Izquierdo</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Expanding antigen-specific regulatory networks to treat autoimmunity</article-title>. <source>Nature</source>. <year>2016</year>;<volume>530</volume>:<fpage>434</fpage>&#8211;<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature16962</pub-id>.<pub-id pub-id-type="pmid">26886799</pub-id></mixed-citation></ref><ref id="cit0085"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anderson</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Landry</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Alkanani</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Pyle</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Powers</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Mathews</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Roep</surname><given-names>BO</given-names></string-name>, <string-name name-style="western"><surname>Michels</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Nakayama</surname><given-names>M</given-names></string-name></person-group>. <article-title>Human islet T cells are highly reactive to preproinsulin in Type 1 diabetes</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2021</year>;<volume>118</volume>:<fpage>118</fpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.2107208118</pub-id>.<pub-id pub-id-type="pmcid">PMC8521679</pub-id><pub-id pub-id-type="pmid">34611019</pub-id></mixed-citation></ref><ref id="cit0086"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaushansky</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kerlero de Rosbo</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zilkha-Falb</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yosef-Hemo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ben-Nun</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>R</given-names></string-name></person-group>. <article-title>&#8216;Multi-epitope-targeted&#8217; immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>11</issue>):<fpage>e27860</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0027860</pub-id>.<pub-id pub-id-type="pmid">22140475</pub-id><pub-id pub-id-type="pmcid">PMC3226621</pub-id></mixed-citation></ref><ref id="cit0087"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De Groot</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Skowron</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Boyle</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Richard</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Serreze</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>WD</given-names></string-name></person-group>. <article-title>Therapeutic administration of tregitope-human albumin fusion with insulin peptides to promote antigen-specific adaptive tolerance induction</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>:<fpage>16103</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-019-52331-1</pub-id>.<pub-id pub-id-type="pmid">31695065</pub-id><pub-id pub-id-type="pmcid">PMC6834854</pub-id></mixed-citation></ref><ref id="cit0088"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nagy</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>de Haas</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Geijtenbeek</surname><given-names>TBH</given-names></string-name>, <string-name name-style="western"><surname>van Ree</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tas</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>van Kooyk</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>de Jong</surname><given-names>EC</given-names></string-name></person-group>. <article-title>Therapeutic liposomal vaccines for dendritic cell activation or tolerance</article-title>. <source>Front Immunol</source>. <year>2021</year>;<volume>12</volume>:<fpage>674048</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2021.674048</pub-id>.<pub-id pub-id-type="pmid">34054859</pub-id><pub-id pub-id-type="pmcid">PMC8155586</pub-id></mixed-citation></ref><ref id="cit0089"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Benne</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ter Braake</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Stoppelenburg</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Broere</surname><given-names>F</given-names></string-name></person-group>. <article-title>Nanoparticles for inducing antigen-specific T cell tolerance in autoimmune diseases</article-title>. <source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>864403</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2022.864403</pub-id>.<pub-id pub-id-type="pmid">35392079</pub-id><pub-id pub-id-type="pmcid">PMC8981588</pub-id></mixed-citation></ref><ref id="cit0090"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kwiatkowski</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Stewart</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Avram</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Keselowsky</surname><given-names>BG</given-names></string-name></person-group>. <article-title>Nano and microparticle emerging strategies for treatment of autoimmune diseases: multiple sclerosis and Type 1 diabetes</article-title>. <source>Adv Healthc Mater</source>. <year>2020</year>;<volume>9</volume>:<fpage>e2000164</fpage>. doi:<pub-id pub-id-type="doi">10.1002/adhm.202000164</pub-id>.<pub-id pub-id-type="pmid">32519501</pub-id><pub-id pub-id-type="pmcid">PMC7588284</pub-id></mixed-citation></ref><ref id="cit0091"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tostanoski</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Chiu</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Gammon</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Simon</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Andorko</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Bromberg</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Jewell</surname>, <given-names>CM</given-names></string-name></person-group>. <article-title>Reprogramming the local lymph node microenvironment promotes tolerance that is systemic and antigen specific</article-title>. <source>Cell Rep</source>. <year>2016</year>;<volume>16</volume>:<fpage>2940</fpage>&#8211;<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.celrep.2016.08.033</pub-id>.<pub-id pub-id-type="pmid">27626664</pub-id><pub-id pub-id-type="pmcid">PMC5024722</pub-id></mixed-citation></ref><ref id="cit0092"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lewis</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Stewart</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname><given-names>GP</given-names></string-name>, <string-name name-style="western"><surname>Carstens</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dolgova</surname><given-names>NV</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Brusko</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Wasserfall</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Clare-Salzler</surname><given-names>MJ</given-names></string-name>, et al</person-group>. <article-title>Dual-sized microparticle system for generating suppressive dendritic cells prevents and reverses Type 1 diabetes in the nonobese diabetic mouse model</article-title>. <source>ACS Biomater Sci Eng</source>. <year>2019</year>;<volume>5</volume>:<fpage>2631</fpage>&#8211;<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acsbiomaterials.9b00332</pub-id>.<pub-id pub-id-type="pmid">31119191</pub-id><pub-id pub-id-type="pmcid">PMC6518351</pub-id></mixed-citation></ref><ref id="cit0093"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kamada</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Moon</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome</article-title>. <source>Adv Drug Deliv Rev</source>. <year>2021</year>;<volume>179</volume>:<fpage>114021</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.addr.2021.114021</pub-id>.<pub-id pub-id-type="pmid">34710529</pub-id><pub-id pub-id-type="pmcid">PMC8665886</pub-id></mixed-citation></ref><ref id="cit0094"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mallone</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Culina</surname><given-names>S</given-names></string-name></person-group>. <article-title>Of bugs and men: antigen-fortified Lactococcus lactis for Type 1 diabetes immunotherapy</article-title>. <source>Diabetes</source>. <year>2014</year>;<volume>63</volume>:<fpage>2603</fpage>&#8211;<lpage>05</lpage>. doi:<pub-id pub-id-type="doi">10.2337/db14-0587</pub-id>.<pub-id pub-id-type="pmid">25060889</pub-id></mixed-citation></ref><ref id="cit0095"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Damo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Watkins</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Hubbell</surname><given-names>JA</given-names></string-name></person-group>. <article-title>Soluble N-acetylgalactosamine-modified antigens enhance hepatocyte-dependent antigen cross-presentation and result in antigen-specific CD8(+) T cell tolerance development</article-title>. <source>Front Immunol</source>. <year>2021</year>;<volume>12</volume>:<fpage>555095</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2021.555095</pub-id>.<pub-id pub-id-type="pmid">33746941</pub-id><pub-id pub-id-type="pmcid">PMC7965950</pub-id></mixed-citation></ref><ref id="cit0096"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mukhopadhaya</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hanafusa</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Jarchum</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YG</given-names></string-name>, <string-name name-style="western"><surname>Iwai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Serreze</surname><given-names>DV</given-names></string-name>, <string-name name-style="western"><surname>Steinman</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Tarbell</surname><given-names>KV</given-names></string-name>, <string-name name-style="western"><surname>DiLorenzo</surname><given-names>TP</given-names></string-name></person-group>. <article-title>Selective delivery of &#946; cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8 + T cells in NOD mice</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2008</year>;<volume>105</volume>:<fpage>6374</fpage>&#8211;<lpage>79</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0802644105</pub-id>.<pub-id pub-id-type="pmid">18430797</pub-id><pub-id pub-id-type="pmcid">PMC2359791</pub-id></mixed-citation></ref><ref id="cit0097"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petzold</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Riewaldt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Koenig</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Schallenberg</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kretschmer</surname><given-names>K</given-names></string-name></person-group>. <article-title>Dendritic cell-targeted pancreatic beta-cell antigen leads to conversion of self-reactive CD4(+) T cells into regulatory T cells and promotes immunotolerance in NOD mice</article-title>. <source>Rev Diabet Stud</source>. <year>2010</year>;<volume>7</volume>:<fpage>47</fpage>&#8211;<lpage>61</lpage>. doi:<pub-id pub-id-type="doi">10.1900/RDS.2010.7.47</pub-id>.<pub-id pub-id-type="pmid">20703438</pub-id><pub-id pub-id-type="pmcid">PMC2923380</pub-id></mixed-citation></ref><ref id="cit0098"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tabansky</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Keskin</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Watts</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Petzold</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Funaro</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sands</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yunis</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Najjar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Diamond</surname><given-names>B</given-names></string-name>, et al</person-group>. <article-title>Targeting DEC-205&#8722;DCIR2+ dendritic cells promotes immunological tolerance in proteolipid protein-induced experimental autoimmune encephalomyelitis</article-title>. <source>Mol Med</source>. <year>2018</year>;<volume>24</volume>:<fpage>17</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s10020-018-0017-6</pub-id>.<pub-id pub-id-type="pmid">30134798</pub-id><pub-id pub-id-type="pmcid">PMC6016871</pub-id></mixed-citation></ref><ref id="cit0099"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Watkins</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Antane</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Lorentz</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Zuerndorfer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dunaif</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Tremain</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>De Loera</surname><given-names>RC</given-names></string-name>, et al</person-group>. <article-title>Persistent antigen exposure via the eryptotic pathway drives terminal T cell dysfunction</article-title>. <source>Sci Immunol</source>. <year>2021</year>;<volume>6</volume>:<fpage>6</fpage>. doi:<pub-id pub-id-type="doi">10.1126/sciimmunol.abe1801</pub-id>.<pub-id pub-id-type="pmid">33637595</pub-id></mixed-citation></ref><ref id="cit0100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Firdessa-Fite</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Creusot</surname><given-names>RJ</given-names></string-name></person-group>. <article-title>Nanoparticles versus dendritic cells as vehicles to deliver mRNA encoding multiple epitopes for Immunotherapy</article-title>. <source>Mol Ther Methods Clin Dev</source>. <year>2020</year>;<volume>16</volume>:<fpage>50</fpage>&#8211;<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.omtm.2019.10.015</pub-id>.<pub-id pub-id-type="pmid">31871957</pub-id><pub-id pub-id-type="pmcid">PMC6909218</pub-id></mixed-citation></ref><ref id="cit0101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Adair</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Yoon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>DW</given-names></string-name></person-group>. <article-title>Human tregs made antigen specific by gene modification: the power to treat autoimmunity and antidrug antibodies with precision</article-title>. <source>Front Immunol</source>. <year>2017</year>;<volume>8</volume>:<fpage>1117</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2017.01117</pub-id>.<pub-id pub-id-type="pmid">28983300</pub-id><pub-id pub-id-type="pmcid">PMC5613123</pub-id></mixed-citation></ref><ref id="cit0102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gottwick</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Carambia</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Herkel</surname><given-names>J</given-names></string-name></person-group>. <article-title>Harnessing the liver to induce antigen-specific immune tolerance</article-title>. <source>Semin Immunopathol</source>. <year>2022</year>;<volume>44</volume>:<fpage>475</fpage>&#8211;<lpage>84</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00281-022-00942-8</pub-id>.<pub-id pub-id-type="pmid">35513495</pub-id><pub-id pub-id-type="pmcid">PMC9256566</pub-id></mixed-citation></ref><ref id="cit0103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rezende</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Weiner</surname><given-names>HL</given-names></string-name></person-group>. <article-title>Oral tolerance: an updated review</article-title>. <source>Immunol Lett</source>. <year>2022</year>;<volume>245</volume>:<fpage>29</fpage>&#8211;<lpage>37</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.imlet.2022.03.007</pub-id>.<pub-id pub-id-type="pmid">35395272</pub-id></mixed-citation></ref><ref id="cit0104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akbarpour</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Goudy</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Cantore</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Russo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Sanvito</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Naldini</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Annoni</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Roncarolo</surname><given-names>MG</given-names></string-name></person-group>. <article-title>Insulin B chain 9&#8211;23 gene transfer to hepatocytes protects from Type 1 diabetes by inducing Ag-specific FoxP3 + T regs</article-title>. <source>Sci Transl Med</source>. <year>2015</year>;<volume>7</volume>:<fpage>289ra81</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.aaa3032</pub-id>.<pub-id pub-id-type="pmid">26019217</pub-id></mixed-citation></ref><ref id="cit0105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cire</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Da Rocha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ferrand</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Galy</surname><given-names>A</given-names></string-name></person-group>. <article-title>In vivo gene delivery to lymph node stromal cells leads to transgene-specific CD8+ T cell anergy in mice</article-title>. <source>Mol Ther</source>. <year>2016</year>;<volume>24</volume>:<fpage>1965</fpage>&#8211;<lpage>73</lpage>. doi:<pub-id pub-id-type="doi">10.1038/mt.2016.168</pub-id>.<pub-id pub-id-type="pmid">27562586</pub-id><pub-id pub-id-type="pmcid">PMC5154481</pub-id></mixed-citation></ref><ref id="cit0106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carey</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Gammon</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Jewell</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Biomaterial-enabled induction of pancreatic-specific regulatory T cells through distinct signal transduction pathways</article-title>. <source>Drug Deliv Transl Res</source>. <year>2021</year>;<volume>11</volume>:<fpage>2468</fpage>&#8211;<lpage>81</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13346-021-01075-5</pub-id>.<pub-id pub-id-type="pmid">34611846</pub-id><pub-id pub-id-type="pmcid">PMC8581478</pub-id></mixed-citation></ref><ref id="cit0107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Vaccination with a co-expression DNA plasmid containing GAD65 fragment gene and IL-10 gene induces regulatory CD4(+) T cells that prevent experimental autoimmune diabetes</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2016</year>;<volume>32</volume>:<fpage>522</fpage>&#8211;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1002/dmrr.2780</pub-id>.<pub-id pub-id-type="pmid">26797873</pub-id></mixed-citation></ref><ref id="cit0108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tanchot</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Barber</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Chiodetti</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>RH</given-names></string-name></person-group>. <article-title>Adaptive tolerance of CD4+ T cells in vivo: multiple thresholds in response to a constant level of antigen presentation</article-title>. <source>J Immunol</source>. <year>2001</year>;<volume>167</volume>:<fpage>2030</fpage>&#8211;<lpage>39</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.167.4.2030</pub-id>.<pub-id pub-id-type="pmid">11489985</pub-id></mixed-citation></ref><ref id="cit0109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Singh</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>RH</given-names></string-name></person-group>. <article-title>The strength of persistent antigenic stimulation modulates adaptive tolerance in peripheral CD4+ T cells</article-title>. <source>J Exp Med</source>. <year>2003</year>;<volume>198</volume>:<fpage>1107</fpage>&#8211;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.20030913</pub-id>.<pub-id pub-id-type="pmid">14530379</pub-id><pub-id pub-id-type="pmcid">PMC2194218</pub-id></mixed-citation></ref><ref id="cit0110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raimondi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zanoni</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Citterio</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ricciardi-Castagnoli</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Granucci</surname><given-names>F</given-names></string-name></person-group>. <article-title>Induction of peripheral T cell tolerance by antigen-presenting B cells. I. Relevance of antigen presentation persistence</article-title>. <source>J Immunol</source>. <year>2006</year>;<volume>176</volume>:<fpage>4012</fpage>&#8211;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.176.7.4012</pub-id>.<pub-id pub-id-type="pmid">16547236</pub-id></mixed-citation></ref><ref id="cit0111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raimondi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zanoni</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Citterio</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ricciardi-Castagnoli</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Granucci</surname><given-names>F</given-names></string-name></person-group>. <article-title>Induction of peripheral T cell tolerance by antigen-presenting B cells. II. Chronic antigen presentation overrules antigen-presenting B cell activation</article-title>. <source>J Immunol</source>. <year>2006</year>;<volume>176</volume>:<fpage>4021</fpage>&#8211;<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.176.7.4021</pub-id>.<pub-id pub-id-type="pmid">16547237</pub-id></mixed-citation></ref><ref id="cit0112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Obst</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>van Santen</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Melamed</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kamphorst</surname><given-names>AO</given-names></string-name>, <string-name name-style="western"><surname>Benoist</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mathis</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>van Santen</surname><given-names>H-M</given-names></string-name></person-group>. <article-title>Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2007</year>;<volume>104</volume>:<fpage>15460</fpage>&#8211;<lpage>65</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0707331104</pub-id>.<pub-id pub-id-type="pmid">17881563</pub-id><pub-id pub-id-type="pmcid">PMC2000557</pub-id></mixed-citation></ref><ref id="cit0113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Noval Rivas</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weatherly</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hazzan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vokaer</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dremier</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gaudray</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Goldman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Salmon</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Braun</surname><given-names>MY</given-names></string-name></person-group>. <article-title>Reviving function in CD4+ T cells adapted to persistent systemic antigen</article-title>. <source>J Immunol</source>. <year>2009</year>;<volume>183</volume>:<fpage>4284</fpage>&#8211;<lpage>91</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.0901408</pub-id>.<pub-id pub-id-type="pmid">19734216</pub-id></mixed-citation></ref><ref id="cit0114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Han</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Asoyan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rabenstein</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nakano</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Obst</surname><given-names>R</given-names></string-name></person-group>. <article-title>Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2010</year>;<volume>107</volume>:<fpage>20453</fpage>&#8211;<lpage>58</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1008437107</pub-id>.<pub-id pub-id-type="pmid">21059929</pub-id><pub-id pub-id-type="pmcid">PMC2996637</pub-id></mixed-citation></ref><ref id="cit0115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Trefzer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kadam</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Pennavaria</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lober</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Akcabozan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kranich</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Brocker</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Nakano</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Irmler</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Dynamic adoption of anergy by antigen-exhausted CD4+ T cells</article-title>. <source>Cell Rep</source>. <year>2021</year>;<volume>34</volume>:<fpage>108748</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.celrep.2021.108748</pub-id>.<pub-id pub-id-type="pmid">33567282</pub-id></mixed-citation></ref><ref id="cit0116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>den Boer</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Diehl</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>van Mierlo</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>van der Voort</surname><given-names>EI</given-names></string-name>, <string-name name-style="western"><surname>Fransen</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Krimpenfort</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>den Boer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>van Mierlo</surname><given-names>GJD</given-names></string-name>, <string-name name-style="western"><surname>van der Voort</surname><given-names>EIH</given-names></string-name>, <string-name name-style="western"><surname>Melief</surname><given-names>CJM</given-names></string-name>, et al</person-group>. <article-title>Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance</article-title>. <source>J Immunol</source>. <year>2001</year>;<volume>167</volume>:<fpage>2522</fpage>&#8211;<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.167.5.2522</pub-id>.<pub-id pub-id-type="pmid">11509591</pub-id></mixed-citation></ref><ref id="cit0117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Redmond</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Hernandez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sherman</surname><given-names>LA</given-names></string-name></person-group>. <article-title>Deletion of naive CD8 T cells requires persistent antigen and is not programmed by an initial signal from the tolerogenic APC</article-title>. <source>J Immunol</source>. <year>2003</year>;<volume>171</volume>:<fpage>6349</fpage>&#8211;<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.171.12.6349</pub-id>.<pub-id pub-id-type="pmid">14662832</pub-id></mixed-citation></ref><ref id="cit0118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Borsotti</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Danzl</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Nauman</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Holzl</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>French</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chavez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Khosravi-Maharlooei</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Glauzy</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Delmotte</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>Meffre</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>HSC extrinsic sex-related and intrinsic autoimmune disease&#8211;related human B-cell variation is recapitulated in humanized mice</article-title>. <source>Blood Adv</source>. <year>2017</year>;<volume>1</volume>:<fpage>2007</fpage>&#8211;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1182/bloodadvances.2017006932</pub-id>.<pub-id pub-id-type="pmid">29296847</pub-id><pub-id pub-id-type="pmcid">PMC5728279</pub-id></mixed-citation></ref><ref id="cit0119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schneider</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rieck</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sanda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pihoker</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Greenbaum</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Buckner</surname><given-names>JH</given-names></string-name></person-group>. <article-title>The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells</article-title>. <source>J Immunol</source>. <year>2008</year>;<volume>181</volume>:<fpage>7350</fpage>&#8211;<lpage>55</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.181.10.7350</pub-id>.<pub-id pub-id-type="pmid">18981158</pub-id><pub-id pub-id-type="pmcid">PMC2597079</pub-id></mixed-citation></ref><ref id="cit0120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Buckner</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Nepom</surname><given-names>GT</given-names></string-name></person-group>. <article-title>Obstacles and opportunities for targeting the effector T cell response in Type 1 diabetes</article-title>. <source>J Autoimmun</source>. <year>2016</year>;<volume>71</volume>:<fpage>44</fpage>&#8211;<lpage>50</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaut.2016.02.009</pub-id>.<pub-id pub-id-type="pmid">26948997</pub-id><pub-id pub-id-type="pmcid">PMC4903876</pub-id></mixed-citation></ref><ref id="cit0121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gearty</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Dundar</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zumbo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Espinosa-Carrasco</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Shakiba</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sanchez-Rivera</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Socci</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Lauer</surname><given-names>P</given-names></string-name>, et al</person-group>. <article-title>An autoimmune stem-like CD8 T cell population drives Type 1 diabetes</article-title>. <source>Nature</source>. <year>2022</year>;<volume>602</volume>:<fpage>156</fpage>&#8211;<lpage>61</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-021-04248-x</pub-id>.<pub-id pub-id-type="pmid">34847567</pub-id><pub-id pub-id-type="pmcid">PMC9315050</pub-id></mixed-citation></ref><ref id="cit0122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grebinoski</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Cillo</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Manne</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Brunazzi</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Tabib</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cardello</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lian</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>GF</given-names></string-name>, et al</person-group>. <article-title>Autoreactive CD8(+) T cells are restrained by an exhaustion-like program that is maintained by LAG3</article-title>. <source>Nat Immunol</source>. <year>2022</year>;<volume>23</volume>:<fpage>868</fpage>&#8211;<lpage>77</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41590-022-01210-5</pub-id>.<pub-id pub-id-type="pmid">35618829</pub-id><pub-id pub-id-type="pmcid">PMC9179227</pub-id></mixed-citation></ref><ref id="cit0123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abdelsamed</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Zebley</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rutishauser</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ghoneim</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Crawford</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Alfei</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Alli</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ribeiro</surname><given-names>SP</given-names></string-name>, et al</person-group>. <article-title>Beta cell-specific CD8(+) T cells maintain stem cell memory-associated epigenetic programs during Type 1 diabetes</article-title>. <source>Nat Immunol</source>. <year>2020</year>;<volume>21</volume>:<fpage>578</fpage>&#8211;<lpage>87</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41590-020-0633-5</pub-id>.<pub-id pub-id-type="pmid">32231298</pub-id><pub-id pub-id-type="pmcid">PMC7183435</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>